Introduction {#s1}
============

During embryonic development, multicellular organisms must generate the patterned tissues of an adult organism from a single undifferentiated cell. This process requires highly regulated control of gene expression, both in developmental time and at reproducible positions in an embryo. These complex gene regulatory networks are controlled by systems of transcription factors, which bind to DNA and control the expression of genes required for development ([@bib37]). In early *Drosophila melanogaster* embryos, Bicoid (Bcd) protein forms an anterior-to-posterior gradient the embryo ([@bib15]). Bcd functions as transcriptional activator to pattern the embryo, binding to target gene enhancers and activating gene expression at distinct positions along the AP axis, corresponding to different concentrations of Bcd protein ([@bib14]; [@bib60]).

Recent studies of Bcd function suggest that its interaction with its targets may be more complex than the simple concentration-dependent activation originally proposed for morphogen gradients ([@bib68]). Embryos in which the graded distribution of Bcd is disrupted still exhibit patterned expression of Bcd target genes, and these genes can be activated at lower concentrations of Bcd than these nuclei would be exposed to in a wild-type embryo ([@bib11]; [@bib41]; [@bib47]). While changing Bcd dosage shifts cell fates, the shifts deviate quantitatively from those expected of strict concentration dependence, especially as expression patterns are assayed progressively later during development ([@bib41]). Because Bcd is not the sole determinant of its target genes' expression domains, their final patterns are also influenced by other maternal patterning systems and interactions among the Bcd targets themselves ([@bib11]; [@bib30]; [@bib42]). Chen *et al*. have shown that the posterior boundaries of Bcd target genes are positioned by a system of repressors including Runt, Krüppel, and Capicua. These studies have consequently raised doubts about the extent to which the local concentration of Bcd determines the spatial patterns of in the embryo. Further, they demonstrate that using target gene expression as a metric for Bcd function cannot directly address how information from the Bcd gradient initially establishes distinct cell fates, as these expression patterns will always be influenced by additional inputs.

Part of the difficulty in evaluating direct roles of the Bcd gradient arises from the unknown nature of the molecular mechanism by which Bcd establishes concentration thresholds at different positions along the gradient. A simple model of the positioning of Bcd target genes predicts that *cis-*regulatory elements of different genes respond to different concentrations of Bcd. Genes in the anterior would have low affinity Bcd binding sites and could therefore only be activated by high Bcd concentrations, whereas genes expressed in more posterior positions would have higher affinity binding sites ([@bib17]). Direct measurements of Bcd binding affinity have been conducted in vitro using DNA probes ([@bib9]; [@bib23]; [@bib71]; [@bib43]) and have demonstrated that Bcd is able to bind cooperatively to achieve sharp concentration thresholds. While these measurements lend some support to a simple affinity model, little correlation has been shown between predicted binding site affinity and AP position of gene expression ([@bib48]; [@bib59]). However, neither in vitro measurements of Bcd binding nor computational predictions of binding sites can capture interactions between Bcd and its target enhancers in the context of local chromatin structure.

In this study, we sought to measure Bcd's interactions with its targets directly in the context of the early embryo. Using high throughput sequencing approaches, we measured in vivo genome-wide Bcd-DNA binding and chromatin accessibility in transgenic embryos expressing different concentrations of uniform Bcd protein. These data reveal distinct classes of DNA targets that differ in their sensitivity to Bcd concentration. We find that these classes differ both in the DNA binding motifs that they contain and in their local chromatin accessibility. We also find that Bcd influences the accessibility of a subset of its target enhancers, primarily at highly concentration-sensitive enhancers that drive gene expression in the anterior of the embryo. This leads us to a model in which target enhancers throughout the genome have a broad range of sensitivities for Bcd protein, and can therefore respond to a range of Bcd concentrations along the gradient. However, rather than arising from differences in Bcd binding site composition, these in vivo interactions are chromatin context-dependent, and Bcd influences the chromatin structure of its target enhancers.

Results {#s2}
=======

Bicoid target gene expression boundaries are influenced by other patterning factors, but its physical interaction with DNA targets is not {#s2-1}
-----------------------------------------------------------------------------------------------------------------------------------------

To investigate the mechanism whereby Bcd functions to pattern the AP axis, we performed chromatin immunoprecipitation followed by high throughput sequencing (ChIP-seq) to determine the genome-wide binding profile of Bcd to its targets. We performed the ChIP-seq experiments on embryos expressing GFP-tagged Bcd in a *bcd* null mutant background that were staged precisely in nuclear cycle 14 (NC14), and established a list of robust and reproducible list of 1027 peak Bcd binding regions (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [Table 1](#table1){ref-type="table"}). These peaks successfully identify 63 of the 66 previously characterized Bcd target enhancers shown to drive expression patterns that span broadly across the AP axis ([@bib11]).
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###### Number of Bcd ChIP-seq peaks at each step of filtering.

                       Number of peaks                              
  -------------------- ----------------- -------- -------- -------- --
  MACS2                29,090            15,429   11,812   38,392   
  IDR                  9815              4245     1464     1329     
  Euchromatic only     2319              4123     1429     1257     
  Common peaks (2/3)                     4126                       
  ATAC-seq ratios      2143              2087                       
  Common Peaks         1027                                         

As a transcriptional regulator, Bcd activates the expression of a subset of its targets whose expression domains are predominantly located in the anterior half of the embryo. In *bcd* mutant embryos, such targets are not expressed. For example, the gap genes *buttonhead* (*btd*) and *knirps* (*kni*) have anterior expression domains that are not present in *bcd* mutant embryos ([Figure 1A](#fig1){ref-type="fig"}). The posterior *kni* expression domain, however, is expressed in *bcd* embryos, albeit with shifted positional boundaries. These distinct domains of *kni* expression are controlled by separate enhancer elements ([@bib49]; [@bib57]), both of which are bound by Bcd in vivo ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). In the absence of all maternal AP patterning inputs (*bicoid nanos hunchback torsolike* \[*bcd nos hb tsl*\] quadruple mutants), *kni* expression is reduced to near-background levels ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) and is not expressed in a posterior stripe. However, in embryos where Bcd is the sole source of maternal patterning information (*nos hb tsl* triple mutants), the *kni* posterior expression domain has a near wild-type level and anterior boundary ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). The *kni* posterior domain therefore represents a second class of Bcd target gene, which depends on Bcd to determine the position of its expression but does not demonstrate an absolute requirement of Bcd for transcriptional activation.

![Uniform Bcd expression specifies cell fates corresponding to levels of expression.\
(**A**) Wild-type, *bcd* null mutant (*bcd^E1^*), and maternal *hunchback, nanos, torso-like (hb nos tsl)* triple mutant and *bcd hb nos tsl* mutant embryos at NC14 immunostained with antibodies against Bcd, Btd, and Kni. Embryos are oriented with anterior to the left. The anterior Kni domain (filled arrow) is absent in *bcd* but restored in *hb nos tsl* embryos, while the posterior stripe (open arrow) shifts anteriorly in in *bcd* but expands posteriorly in *hb nos tsl.* Neither Btd nor Kni exhibit patterned expression in *bcd hb nos tsl*. Images are maximum z-projections and image contrast was adjusted uniformly across the entire image for display. See [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} for quantification of Kni intensity between genotypes. (**B**) Expression levels of uniform GFP-Bcd transgenic constructs relative to wild-type Bcd expression. Live embryos were imaged in during NC14, and dorsal profiles were plotted. Error bars are standard error of the mean. For wild-type, n = 23 embryos; *bcd*-uBcd n = 13; *mtrm*-uBcd n = 7; and *αTub67C*-uBcd n = 14. See also [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"} and [Table 6](#table6){ref-type="table"}. (**C**) Immunostaining as (**A**), for each level of uniform Bcd. Anterior target gene expression is absent at the lowest level. At intermediate (*mtrm*) and high (*αTub67C*) levels of uBcd, anterior expression patterns are expanded and/or duplicated in the posterior, and posterior expression of Kni is absent. (**D**) Larval cuticle preparations for the indicated genotypes. Embryos are oriented with anterior at the top. Head structures are indicated with open arrows and tail structures with filled arrows. *αTub67C* \>uBcd embryos develop essentially no cuticle tissue, but form only what appear to be anteriorly-derived mouth structures. *mtrm* \>uBcd results in a duplication of the anterior-most abdominal denticles in the anterior and posterior of the embryo, with no clear terminal structures forming at either end. *bcd* \>uBcd embryos have a normal posterior and all abdominal segments, but no thoracic or head structures. Images of individual embryos were rotated and cropped to exclude nearby embryos and air bubbles.](elife-28275-fig1){#fig1}

Both classes of Bcd target genes receive positional cues both from Bcd and from other patterning systems. We considered the possibility that, given their influence on the expression domains of Bcd target genes, the posterior and terminal patterning systems may impact Bcd binding to its target enhancers in different nuclei along the AP axis. We therefore tested whether loss of the posterior and terminal systems (*nos* and *tsl*) would alter the Bcd ChIP-seq profile. We used the statistical package EdgeR ([@bib54]) to test for differential Bcd binding between wild-type and *nos tsl* embryos and found that we could not detect any significant change in binding at any of these 1027 regions ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Therefore, although the expression domains of Bcd target genes are ultimately influenced by inputs from other AP patterning systems, the physical interaction of Bcd with DNA occurs independently of other maternal AP patterning inputs.

Embryos expressing bcd uniformly show developmental fates reflecting the concentration of bcd {#s2-2}
---------------------------------------------------------------------------------------------

We set out to test whether incremental changes in Bcd concentration along the gradient can be read out directly at the level of binding to target enhancers. Due to the graded distribution of Bcd, each nucleus along the AP axis is exposed to a different concentration of the protein. To measure the Bcd binding state at individual concentrations, we performed ChIP-seq on embryos expressing Bcd at single, uniform concentrations in every nucleus along the AP axis. Several previous studies have included genetic manipulations in which the Bcd gradient has been flattened to assess its activity independently of its distribution ([@bib11]; [@bib14]; [@bib42]; [@bib47]). However, genetically disrupting the gradient does not result in a total flattening, and transgenic approaches to date have not allowed for precise and reproducible control over the level of expression of the flattened Bcd. We therefore generated transgenic lines expressing GFP tagged Bcd in which the endogenous 3'UTR responsible for graded localization is flanked by FRT sites that allow it to be replaced with the unlocalized *spaghetti squash* 3'UTR. To generate different expression levels of uniform Bcd, we coupled transgenes to different maternally active promoters that yield embryos in which individual uniform Bcd concentration approximates single positions along the gradient (see [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}).

To determine the expression levels of the uniform lines, we imaged GFP fluorescence in live embryos expressing either uniform or graded GFP-Bcd ([@bib26]) ([Figure 1B](#fig1){ref-type="fig"}). The endogenous *bcd* promoter drives a level of uniformly expressed Bcd equivalent to that measured at approximately 65% egg length of the wild-type gradient. The *matrimony (mtrm)* and *αTubulin67C (αTub67C)* promoters drive expression levels corresponding to approximately 45% and 25% egg length, respectively. For simplicity, we refer to the uniform lines as low (*bcd* promoter), medium (*mtrm* promoter), and high (*αTub67C* promoter). (See also [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"})

Uniform expression of Bcd confers gene expression profiles and developmental programs representative of distinct positions along the AP axis. The head gap gene *buttonhead (btd)* is expressed in an anterior stripe in wild-type embryos ([Figure 1A](#fig1){ref-type="fig"}), but expands to fill the entire middle of the embryo at the highest level of uniform Bcd ([Figure 1C](#fig1){ref-type="fig"}). At the medium level, the Btd anterior stripe is duplicated at the posterior, and at the lowest Bcd level, it is not expressed. The gap gene *knirps*, which is expressed in an anterior domain and a posterior stripe, shows a duplication of its anterior domain in the posterior in high uniform Bcd embryos. There is also a weaker duplication at the medium Bcd level. There is no apparent anterior expression at the lowest level, but an expanded posterior stripe is present. The gene expression patterning we observe in the presence of uniform Bcd likely results from the activity of additional maternal patterning cues (*nanos* and *torso*) as well as interactions between the Bcd target genes themselves. The concentration-dependent activity of uniform Bcd is also apparent in cuticle preparations of embryos expressing the transgenic constructs. The transgenic constructs specify increasingly anterior structures along larval body plan as the concentration of Bcd increases ([Figure 1D](#fig1){ref-type="fig"}). These effects on the body plan indicate that the uniform Bcd transgenes can specify cell fates that reflect their relative expression levels.

Bcd binding to genomic targets is concentration dependent {#s2-3}
---------------------------------------------------------

We next determined genome-wide Bcd binding profiles at each individual concentration by ChIP-seq and used these measurements to assign each of the 1027 peak regions to classes distinguished by their degree of concentration-dependent Bcd binding ([Figure 2A](#fig2){ref-type="fig"}). Using EdgeR ([@bib54]), we selected peak regions that exhibited statistically significant (FDR ≤ 0.05) differences in binding by performing pairwise exact tests between the three uniform Bcd concentrations. This yielded four different classes of peaks, one concentration-insensitive class, and three classes with increasing sensitivity to Bcd concentration.

![Bcd-bound regions are classified into groups of increasing sensitivity to Bcd concentration.\
(**A**) ChIP-seq data in Bcd-bound peaks. Data is displayed as a heatmap of z-score normalized ChIP-seq reads, in a 2 kilobase region centered around each peak. Peaks in each class are arranged in order of decreasing z-scores in wild-type embryos. One peak (peak 549, see [Supplementary file 1](#supp1){ref-type="supplementary-material"}) was not classified, as it showed increasing binding at decreasing Bcd concentrations. Previously characterized enhancers overlapping with each class are indicated at right. Concentration-Insensitive: the posterior stripe enhancers for both *knirps* ([@bib49]) and *giant* ([@bib57]), and the *Krüppel* CD1 enhancer ([@bib28]). Concentration-Sensitive III: *cap'n'collar* ([@bib57]), and *huckebein* ([@bib29]) enhancers. Concentration-Sensitive II: the *hunchback* P2 proximal ([@bib60]) and shadow enhancers ([@bib50]), the *even-skipped* stripe 2 enhancer ([@bib24]), an early *paired* enhancer ([@bib48]), and an anterior enhancer for *giant* ([@bib57]). Concentration-Sensitive I: *buttonhead* ([@bib67])*, orthodenticle* ([@bib23]), and anterior enhancers for both *knirps* and *giant* ([@bib57]). (**B**) Mean expression patterns of Vienna Tile-GAL4 enhancer reporters overlapping with Bcd peaks in each sensitivity class. Peaks and Vienna Tiles with more than one overlap, as well as 11 Vienna Tiles that drove expression at a level too low to quantify, were excluded from the plot. (**C**) Top DNA motifs discovered by RSAT peak-motifs. The e-value for is a p-value computed from a binomial distribution for a given motif in the dataset, corrected for multiple testing. See [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} for de novo motif discovery in each sensitivity class. (**D**) Heatmap displaying the enrichment of a given motif in each sensitivity class, relative to the peak list as a whole. P-values were generated from permutation tests (n = 10,000 tests).](elife-28275-fig2){#fig2}

The Concentration-Insensitive peak class (n = 143) shows no significant differences between any of the concentrations of uniform Bcd we tested. Concentration-Sensitive III peaks (n = 593) are significantly reduced in binding between the highest and lowest Bcd concentrations, but reductions are not significant between high and medium, or medium and low. Concentration-Sensitive II peaks (n = 138) are significantly reduced in binding at the lowest Bcd level compared to either the medium or the high levels. Finally, Concentration-Sensitive I peaks (n = 152) are significantly reduced in binding at both the medium and the low Bcd levels compared to the highest level ([Figure 2A](#fig2){ref-type="fig"}). These different groups suggest that Bcd binds differentially to its targets at specific concentrations, and furthermore that certain subsets of these targets are bound only in anterior nuclei whereas others are bound broadly across the entire AP axis.

Although 63 out of 66 previously characterized Bcd-dependent enhancers are identified in our ChIP peaks, the majority of the 1027 peaks identified have not been extensively examined. Within the set of known Bcd targets, there is strong correlation between position of expression and the associated Bcd sensitivity class ([Figure 2A](#fig2){ref-type="fig"}). To extend this observation to previously uncharacterized Bcd targets, we queried the Fly Enhancer resource generated from the Vienna Tile GAL4 reporter library ([@bib33]). The Fly Enhancer collection is a library of candidate enhancer DNA fragments (Tiles) driving expression of GAL4 that covers 13.5% of the non-coding genome. Each Tile's expression pattern has been measured and scored by developmental stage. A total of 293 Tiles overlap with at least one peak in our data set. Of these, 163 drive gene expression in stage 4--6 (which includes NC14), and these active Tiles overlap with a total of 151 (14.7%) of the Bcd-peaks ([Table 2](#table2){ref-type="table"}). The remaining overlapping Tiles either are active later in development (75), or are not functional (55). The fraction of the 293 Tiles that overlap with Bcd peaks and are active during early development (163, or 55.6%) is significantly higher than the proportion of Tiles active in early embryos for the collection as a whole (666 of the total 7793 or 8.5%). This suggests that the Bcd binding peaks are significantly enriched for enhancer activity, and that a similar fraction of the remaining 793 Bcd peaks not present in the Fly Enhancer collection may correspond to active enhancers as well.
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###### Number of overlapping Bcd ChIP peaks and Vienna Tile-GAL4 enhancer reporters.

Note that some Bcd peaks overlap with more than one Vienna Tile, and vice versa. The reporters expressed at stage 4--6 that overlapped with more than one Bcd peak were excluded from the plot in [Figure 2B](#fig2){ref-type="fig"}.

  --------------------------------------------------------------------
  Overlaps with Vienna Tile-GAL4 reporters                       
  ------------------------------------------ ------- ----- ----- -----
  Active\                                    3604    238   193   127
  (all stages)                                                   

  Active\                                    666     163   151   115
  (stage 4--6)                                                   

  Patterned (stage 4--6)                     627\*   159   147   112

  Not Active                                 4189    55    41    28

  Total                                      7793    293   234   155
  --------------------------------------------------------------------

\*The patterned expression from the 666 Vienna Tiles that drive expression at stage 4--6 was determined by subtracting the number of tiles scored as 'ubiquitous' (39) from the total number of tiles.

The proportion of peaks overlapping with active enhancers in the Fly Enhancer library varies by sensitivity class. While the Concentration-Sensitive III peaks are the largest class, they have the lowest representation in the Fly Enhancer collection, with 18% of peaks overlapping with a Vienna Tile enhancer reporter. Of these overlapping peaks, 52% overlap with Tiles active at stage 4--6, a smaller fraction than observed for the other peak classes which range from 73% to 77% (see [Table 3](#table3){ref-type="table"}). We also observe differences in the proximity of peaks in each class to transcription start sites (TSS), with the Concentration Sensitive III and Concentration-Insensitive classes being nearly twice as likely to lie within 500 bp of a TSS (see [Table 4](#table4){ref-type="table"}). Although highly accessible regions such as promoters are common artifacts in ChIP-seq data ([@bib63]), we made substantial efforts to remove these artifacts (see Materials and methods). It is possible that the large Concentration-Sensitive III class contains peaks where Bcd binds opportunistically and its binding does not necessarily result in active gene expression, as has been observed in ChIP-seq datasets ([@bib3]). However, the large overlap between active enhancers in the Fly Enhancer database and our peaks list suggests that every class contains functional enhancers beyond those that have been previously examined.

10.7554/eLife.28275.009

###### Number of Bcd ChIP-seq peaks in each class overlapping with Vienna Tile-GAL4 reporters.

Queried Bcd peaks are peaks that are present in the Fly Enhancer database, whose expression can be assessed.

  Overlaps of peak classes with active enhancers and transcription start sites                                      
  ------------------------------------------------------------------------------ ----- ------- ---- ------- ------- -----
  Concentration-Sensitive I                                                      52    34.2%   38   73.1%   25.0%   152
  Concentration-Sensitive II                                                     38    27.5%   29   73.7%   21.0%   138
  Concentration-Sensitive III                                                    109   18.4%   57   52.3%   9.6%    593
  Concentration-Insensitive                                                      34    23.8%   26   76.5%   18.2%   143
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###### Number of Bcd ChIP-seq peaks in each class within 500 bp Transcription Start Sites.

  Bcd peak class                Overlaps with TSS   Total bcd peaks   
  ----------------------------- ------------------- ----------------- -----
  Concentration-Sensitive I     29                  19.1%             152
  Concentration-Sensitive II    35                  25.4%             138
  Concentration-Sensitive III   291                 49.1%             593
  Concentration-Insensitive     74                  51.7%             143

The Bcd sensitivity classes are predictive of the expression domains of associated enhancer fragments. Enhancers overlapping with both the Concentration-Sensitive I and II classes drive expression in anterior regions of the embryo, with the Concentration-Sensitive III and Concentration-Insensitive classes driving broad and posterior expression, respectively ([Figure 2B](#fig2){ref-type="fig"}). This indicates that our classifications of the Bcd-bound peaks reflect unique groups of Bcd targets with differing abilities to bind Bcd protein and consequently activate gene expression in different positions along the AP axis.

Sequence composition of ChIP sensitivity classes does not account for in vivo sensitivity to bcd concentration {#s2-4}
--------------------------------------------------------------------------------------------------------------

We next wanted to determine whether the Bcd-bound regions in each sensitivity class differ at the level of DNA sequence. In vitro, Bcd binds with high affinity to the consensus 5\'-TCTAATCCC-3\', and that variations on this consensus sequence constitute weak binding sites ([@bib9]; [@bib16]; [@bib17]). If the affinity of a given enhancer for Bcd were encoded primarily at the level of its DNA sequence, we would expect to see a higher representation of strong Bcd binding sites in the less sensitive classes, and weaker sites in the more sensitive classes. To test this, we performed de novo motif discovery using the RSAT peak-motifs algorithm ([@bib64]; [@bib65]). We identified the top motifs in the entire Bcd ChIP peak list, ranked by their e-value, and found that the top three most highly ranked motifs were the consensus binding site for the proposed pioneer factor Zelda (Zld) ([@bib62]; [@bib13]; [@bib27]; [@bib46]), and a strong (TAATCC) and weak (TAAGCC) Bcd binding site ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We next calculated the frequency with which these motifs appear in each peak, and tested for enrichment between sensitivity classes by permutation test ([Figure 2D](#fig2){ref-type="fig"}). We found that despite their failure to bind Bcd at low concentrations, the Concentration-Sensitive I and II classes are enriched for both the strong and weak Bcd sites relative to the peak set as a whole. The Concentration-Sensitive III class did not contain an enrichment of any site over the total peak set. The Concentration-Insensitive class, however, showed a higher prevalence of the Zld binding site relative to the total peak set than any other class.

[@bib48] found little correlation between either the number or strength of Bcd binding sites in an enhancer and the position of gene expression driven by that enhancer. Given our result that the Concentration-Sensitive I and II classes drive expression primarily in the anterior of the embryo ([Figure 2B](#fig2){ref-type="fig"}), the higher density of Bcd binding sites in these peaks indicates that there is, in fact, a correlation between the binding site number and position of gene expression. This difference likely reflects the larger sample size used in our study, as well as our method for classifying Bcd bound peaks. However, in contrast to a binding site affinity model for Bcd function, Bcd targets that behave as concentration-sensitive and -insensitive in vivo are not distinguished by their representation of strong versus weak Bcd binding sites, partially confirming the previous study ([@bib48]).

In further support of this concept, we found little correlation between in vitro binding affinity by electrophoretic mobility shift assay and the in vivo binding properties we observe by ChIP for a selected subset of peaks ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). At the level of sequence composition, they instead appear to differ in their balance of Bcd and Zld binding sites. Although both strong and weak Bcd sites and Zld sites are enriched in the Bcd ChIP peaks as a whole, there is a bias toward both Bcd sites in peaks that show concentration-sensitive binding properties by ChIP-seq and a bias toward Zld sites in the concentration-insensitive peaks. Zld, a ubiquitously expressed early embryonic transcription factor, has been implicated in chromatin remodeling prior to zygotic genome activation ([@bib27]; [@bib46]; [@bib61]). The predominance of Zld motifs over Bcd motifs in the Concentration-Insensitive class suggests that in vivo chromatin structure also plays a role in the sensitivity of a given target to transcription factor concentration in the context of the developing embryo. Taken together, these findings suggest that the chromatin context of an enhancer may play a greater role in its overall affinity for a transcription factor in vivo than the sequences of the binding sites that it contains. We therefore set out to test the hypothesis that sensitivity classes are distinguished at the level of chromatin structure.

Bcd is required for chromatin accessibility at a subset of concentration-sensitive target sites {#s2-5}
-----------------------------------------------------------------------------------------------

To measure genome-wide patterns of chromatin accessibility and nucleosome positioning, we performed ATAC-seq ([@bib7]) on single wild-type embryos precisely staged at 12 min after the onset of NC14, and identified 13,266 peaks of chromatin accessibility (see Materials and methods). Of the 1,027 Bcd-bound regions identified by ChIP-seq, 855 (83.3%) of them overlap with ATAC-seq peaks.

Given Zelda\'s role in influencing chromatin accessibility and the presence of its binding sites at Bcd-bound regions of genome, we measured the effect of Zld on accessibility at Bcd sites by ATAC seq ([Figure 3A](#fig3){ref-type="fig"}). Of the total 13,226 accessible regions at NC14, 2675 (20.2%) show a significant reduction in accessibility in *zld* mutant embryos. This fraction is higher in Bcd-bound peaks; 402 (39.1%; or 379 \[44.3%\] of the 855 Bcd peaks that overlap with ATAC open regions, see [Table 5](#table5){ref-type="table"}) show reduced accessibility in *zld* mutants, indicating that Bcd bound regions are more likely to be dependent on Zld for their accessibility than the genome as a whole. However, the Zld-dependent peaks are distributed across each sensitivity class determined by ChIP, with no particular class being significantly more Zld-dependent ([Figure 3B](#fig3){ref-type="fig"}). This contrasts with the distribution of binding sites in the peak classes, which revealed that the Concentration-Insensitive peaks were more likely to contain Zld binding sites. However, if the Bcd peaks are separated into those bound and not bound by Zld, we do observe an enrichment of the Concentration-Insensitive peaks in Zld-dependent, Zld-bound peaks ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). These results suggest that while Zld contributes to the accessibility of a subset of Bcd targets, it is unlikely to be the sole determinant of the differential concentration sensitivity of Bcd peaks as a whole.

10.7554/eLife.28275.011

###### Number of peaks dependent on Bcd or Zld for chromatin accessibility.

ATAC +ChIP common peaks are peaks that overlap between the Bcd ChIP-seq peaks and the wild-type ATAC-seq open chromatin peaks.

  ----------------------------------------------------------------------------------
  Peak list                   Bcd\        Zld\        Bcd + Zld dependent   Total
                              Dependent   Dependent                         
  --------------------------- ----------- ----------- --------------------- --------
   ATAC Open Peaks            326         2675        206                   13,226

   Bcd ChIP Peaks             132         402         61                    1027

   ATAC + ChIP Common Peaks   121         379         58                    855
  ----------------------------------------------------------------------------------

![Bcd drives chromatin accessibility primarily at concentration-sensitive targets.\
(**A**) Heatmaps showing chromatin accessibility (top) and probability of nucleosome occupancy (bottom) around Bcd-bound peaks from ATAC-seq experiments. Peak regions are arranged by decreasing accessibility in wild-type embryos. *bcd^E1^* mutant embryos show a loss of accessibility and increased nucleosome occupancy most strongly at the Concentration-Sensitive I and II peaks. *zld^-^* embryos show reduced accessibility across all sensitivity classes. (**B**) Subset of 132 Bcd-bound peaks selected from (**A**) that become inaccessible in the absence of Bcd. Accessibility at these peaks increases with increasing concentrations of uniform Bcd. Odds ratios and p-values calculated from Fisher\'s exact test show significant overrepresentation of the Concentration-Sensitive I and II classes in the Bcd- and Zld-dependent peaks. n values indicate the number of peaks in each sensitivity class that are Bcd or Zld dependent.](elife-28275-fig3){#fig3}

Given the enrichment for both strong and weak Bcd binding sites in the Concentration-Sensitive I and II classes, we next examined the impact of Bcd protein itself on chromatin accessibility by ATAC-seq ([Figure 3A](#fig3){ref-type="fig"}). In *bcd* mutants, 326 (2.4%) of the 13,266 open regions in wild-type embryos show significantly reduced accessibility accompanied by increased nucleosome occupancy in those same regions ([Figure 3A and B](#fig3){ref-type="fig"}). These regions are therefore either directly or indirectly dependent on Bcd for their accessibility. More strikingly, 132 (12.9%) of the 1,027 Bcd ChIP-seq peaks show reduced accessibility in the absence of Bcd and likely represent regions where Bcd's impact is direct. These regions dependent on Bcd for accessibility are significantly enriched for peaks in the Concentration-Sensitive I and II classes (32.9% and 31.9% of each class, with Fisher's exact test P-values of 4.29 × 10^−12^ and 1.37 × 10^−10^, respectively). In contrast, the Concentration-Sensitive III and Concentration-Insensitive classes are both significantly underrepresented (6.07% and 0.7% and p-values=7.88×10^−13^ and 2.29 × 10^−8^) ([Figure 3B](#fig3){ref-type="fig"}). This suggests that Bcd binding influences chromatin accessibility preferentially at a subset of highly concentration-sensitive targets.

Because the Concentration-Sensitive I and II classes are bound primarily at high Bcd concentrations, Bcd\'s effects on chromatin accessibility at these targets likely occurs only in anterior regions of the embryo. In support of this, we find that chromatin accessibility at Bcd-dependent, concentration-sensitive targets is responsive to Bcd concentration. Expressing uniform Bcd confers accessibility to peaks that are not accessible in *bcd* mutant embryos ([Figure 3B](#fig3){ref-type="fig"}). The degree of chromatin accessibility conferred by Bcd correlates positively with the concentration of uniform Bcd expressed ([Figure 3B](#fig3){ref-type="fig"}). This observation, along with the overrepresentation of the Concentration-Sensitive I and II classes in the Bcd-dependent peaks, suggests that Bcd influences the chromatin state of these targets primarily at the high concentrations found in the anterior of the embryo.

A second feature that distinguishes the chromatin structure of Bcd binding sites is the presence of DNA sequences favorable for nucleosome occupancy ([@bib58]). Bcd bound regions in wild-type embryos are generally depleted of nucleosomes ([Figure 4A](#fig4){ref-type="fig"}). However, predicting nucleosome positioning sequences using the NuPoP algorithm ([@bib69]) suggests that the Concentration-Sensitive I and II Bcd peak classes are more likely to bind nucleosomes than the Concentration-Sensitive III and Concentration-Insensitive classes. ([Figure 4B](#fig4){ref-type="fig"}). The contrast between predicted occupancy and observed depletion suggests that these regions are actively restructured for Bcd and other transcription factors to bind. The increased nucleosome preference of the more Concentration-Sensitive peaks, combined with the observation that these sites become occupied by nucleosomes in *bcd* mutants suggests a model where Bcd, either directly or in combination with cofactors is able to direct chromatin remodeling events, which may play a significant role in distinguishing concentration-sensitive and -insensitive targets. Additionally, we find that Bcd-bound regions that are dependent on either Zld or Bcd for their accessibility are more likely to have a higher nucleosome preference than regions that are independent of both factors ([Figure 4C](#fig4){ref-type="fig"}). This further suggests that Bcd is able to overcome a high nucleosome barrier in a manner similar to Zld ([@bib61]) at a subset of its target enhancers.

![Bcd sensitivity classes differ in both predicted and observed nucleosome occupancy.\
(**A**) Metaprofiles of nucleosome occupancy in each sensitivity class in wild-type embryos. Background represents random selection of regions outside of Bcd peaks shows a genome-wide average nucleosome probability of \~0.6. Bcd-bound peak regions show reduced nucleosome occupancy compared to unbound regions. (**B**) Predicted nucleosome occupancy using NuPoP show higher modeled probability of nucleosome occupancy in Bcd-bound peaks relative to background regions, with higher probability of occupancy at the Concentration-Sensitive I and II classes. (**C**) Predicted nucleosome occupancy in peaks dependent on Bcd vs. Zld (n~Bcd~ = 132 peaks, n~Zld~ = 402 peaks, with n = 61 peaks dependent on both Bcd and Zld) for accessibility show higher predicted occupancy than peaks independent of both Bcd and Zld (n = 554). (**D**) Mean wild-type (black) or *bcd^--^* (red) ATAC accessibility scores for Bcd motifs were calculated for each peak and plotted by sensitivity group. Boxplots depict the distribution of accessibility scores for each group in each genotype, and individual data points are shown as points. P-values were calculated by one-sided permutation test and indicate the likelihood in a randomly selected population of observing a difference between means greater than the observed values (p\<1e-6 for Concentration-Sensitive I and II groups, p=0.001207 for Concentration-Sensitive III, and p=0.988167 for Concentration-Insensitive).](elife-28275-fig4){#fig4}

These effects of chromatin accessibility impact the availability of sequence motifs for binding Bcd. In wild-type embryos, there is a gradual increase in average motif accessibility from high to low sensitivity, and this difference becomes more pronounced in *bcd* mutant embryos ([Figure 4D](#fig4){ref-type="fig"}), consistent with a role for Bcd in driving changes in accessibility at more sensitive sites in a concentration dependent manner. This is also evident at the level of nucleosome organization. Calculating the fraction of motifs that overlap nucleosomes in either wild-type or *bcd* mutant chromatin conformations, we find that whereas on average across all sensitivity classes 55 ± 2% of Bcd motifs are in nucleosome-free tracts in wild-type embryos, in *bcd* mutant embryos motifs have lower overall accessibility and a graded association with nucleosomes that correlates with the sensitivity classes (41%, 46%, 50%, and 53% of motifs are accessible from high to low sensitivity). These results indicate that the mechanistic determinants of concentration-dependent Bcd action likely involve a complex interaction between Bcd, DNA, and chromatin structure.

A truncated bcd protein shows reduced binding specifically at concentration-sensitive targets {#s2-6}
---------------------------------------------------------------------------------------------

A chromatin remodeling activity associated with Bcd has not been previously described. We hypothesize that Bcd renders its target sites accessible either by competing with nucleosomes to access its binding sites and bind to DNA at high concentrations or by recruiting chromatin-remodeling enzymes to accessible motifs and subsequently driving local nucleosome remodeling to render more sites accessible. We reasoned that if Bcd can displace nucleosomes simply by competing with them for access to its binding sites, it should be possible for the Bcd DNA-binding homeodomain to compete. However, if Bcd instead drives remodeling via recruitment of cofactors, it is likely that these interactions or activities are carried out through regions of the protein outside of the DNA binding domain. To distinguish between these two possibilities, we designed a transgenic GFP-Bcd construct that is truncated downstream of the homeodomain. We modeled the truncated Bcd protein after the *bcd^085^* allele, which was originally classified as an 'intermediate allele' of *bcd* ([@bib20]) and reported to have weak transcriptional activating activity ([@bib60]). The truncation occurs 28 amino acids downstream of the homeodomain ([Figure 5A](#fig5){ref-type="fig"}), and the GFP-tagged protein was therefore expected to bind DNA but lack functions requiring its C-terminus. The truncated protein (known as GFP-Bcd^085^) forms a gradient from the anterior of the embryo, and is expressed at a similar level as a full-length GFP-Bcd ([Figure 5B](#fig5){ref-type="fig"}).

![Bcd requires C-terminal protein domains to bind to concentration-sensitive targets.\
(**A**) GFP-Bcd^085^ construct is truncated within the S/T domain downstream of the homedomain. Wild-type protein domains modified from ([@bib32]) and ([@bib12]). The N-terminus of the protein includes a PRD repeat, followed by the DNA-binding homeodomain (HD) ([@bib2]). The serine/threonine-rich (S/T) domain is the target of MAPK phosphorylation by the terminal patterning Torso pathway ([@bib31]) and contains a PEST sequence implicated in targeting the protein for degradation (Rechsteiner and Rogers, 1996). The C-terminus contains three domains implicated in transcriptional activation. The glutamine-rich (**Q**)/OPA and alanine-rich (**A**) domains are required for interactions with TAFII110 and TAFII60, respectively ([@bib55]). The acidic (**C**) domain has been demonstrated to play a role in transcriptional activation in yeast, but is not required for Bcd activity in the embryo ([@bib17]). (**B**) GFP-Bcd^085^ forms a protein gradient comparable to wild-type GFP-Bcd. GFP fluorescence intensity was extracted from dorsal profiles of live embryos. Error bars are standard error of the mean: GFP-Bcd embryos, n = 8; and GFP-Bcd^085^ embryos, n = 8. (**C**) Boxplots displaying log transformed CPM normalized ChIP-seq data from *GFP-Bcd;;bcd^E1^* (wild-type) and *GFP-Bcd^085^;bcd^E1^* (Bcd^085^) embryos show significant reduction binding of Bcd^085^ in Concentration-Sensitive I and II peaks. P-values were calculated from permutation tests (n = 10,000).](elife-28275-fig5){#fig5}

While it is difficult to determine whether the homedomain structure is completely intact in the GFP-Bcd^085^ construct, we tested the ability to the truncated protein to bind to Bcd target sequences compared to a wild-type GFP-Bcd protein. By ChIP-seq, we found that GFP-Bcd^085^ binding in the Concentration-Sensitive I and II peak classes was significantly reduced compared to wild-type (p-values\<0.0001 in permutation test with n = 10,000 trials), while binding to the Concentration-Sensitive III and Concentration-Insensitive classes was not ([Figure 5C](#fig5){ref-type="fig"}). Our ATAC-seq experiments revealed that these classes have reduced chromatin accessibility in *bcd* mutants ([Figures 3B](#fig3){ref-type="fig"} and [4D](#fig4){ref-type="fig"}). Taken together, these results suggest that Bcd\'s ability to access its concentration-sensitive targets is dependent upon activities carried out by domains in the C-terminus of the protein, likely via recruitment of a cofactor, and that its DNA binding activity alone is insufficient to drive chromatin accessibility.

Bicoid binding sites confer anterior expression to a posterior target {#s2-7}
---------------------------------------------------------------------

Overall, highly concentration-dependent targets are expressed in the anterior and are dependent on Bcd for accessibility, while less sensitive targets show more posterior expression patterns and a greater enrichment for Zld binding sites. An enhancer for *caudal* is a Concentration-Insensitive Bcd target and drives expression in the posterior of the embryo ([Figure 6](#fig6){ref-type="fig"}). This enhancer depends on Zld for chromatin accessibility, and consequently is not functional in *zld* mutants ([Supplementary file 1](#supp1){ref-type="supplementary-material"} and [Figure 6B](#fig6){ref-type="fig"}). This supports previous findings that Zld binding contributes to allowing Bcd activation at low concentrations in posterior nuclei ([@bib70]). Like the *kni* posterior enhancer ([Figure 1A](#fig1){ref-type="fig"}), the *caudal* enhancer is Bcd independent for chromatin accessibility and its expression boundary shifts anteriorly in *bcd* mutant embryos. We tested whether we could convert the properties of the *caudal* enhancer from low to high sensitivity by manipulating DNA motifs. We identified the Zld binding sites in the *caudal* enhancer sequence and mutated them to Bcd binding sites ([Figure 6A](#fig6){ref-type="fig"}). These mutations result in a shift of *caudal* reporter expression to the anterior of the embryo. Anterior expression of the mutated reporter is Bcd dependent, as it is lost in *bcd* mutant embryos. Importantly, the mutant enhancer is functional in *zld* mutant embryos, retaining a distinct anterior expression domain. In the absence of Zld binding, the wild-type enhancer does not drive expression ([Figure 6B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). By replacing Zld motifs with Bcd motifs, the enhancer retains functionality, but the spatial domains of expression are now restricted to regions of high Bcd concentration. While technical limitations prevented us from measuring chromatin accessibility of the reporter constructs directly, these results are consistent with a model where Bcd operates at high concentrations to confer chromatin accessibility at target sites. Previous work has demonstrated that addition of Zld sites to an inactive DNA fragment (HC_45) can transform it into an enhancer that drives gene expression early in development ([@bib70]). We found that adding Bcd sites instead of Zld sites to this same reporter also activates expression from the enhancer in an anterior stripe ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). These data support a model where Bcd delineates distinct gene expression and chromatin states at specific positions along its concentration gradient.

![Replacing Zld sites with Bcd sites shifts gene expression to the anterior.\
(**A**) Schematic of the Vienna Tile enhancer reporter for *caudal*, containing 5 Zld and 6 Bcd binding sites. The mutated reporter contains 11 Bcd binding sites and no Zld sites. (**B**) Expression of the wild-type and mutated reporter in wild-type, *bcd ^--^*or *zld ^--^* embryos.](elife-28275-fig6){#fig6}

Discussion {#s3}
==========

A model for chromatin accessibility thresholds at bcd target genes {#s3-1}
------------------------------------------------------------------

The results presented here demonstrate that the positional information in the Bcd gradient is read out as differential binding between Bcd and the *cis-*regulatory regions of its target genes. The overrepresentation of enhancers for anteriorly expressed target genes in the more sensitive classes provides support for the classic French flag model, as their enhancers are only capable of binding Bcd at high levels. However, motif analysis and in vitro EMSA experiments reveal that the differences in binding affinities that we observe in vivo cannot be explained entirely by the sequence of Bcd binding sites in the target enhancers. Instead we find that a subset of the enhancers in the concentration-sensitive classes require Bcd for chromatin accessibility. Taken together, this leads us to model in which the Bcd morphogen establishes concentration thresholds along the AP axis of the developing embryo by driving opening chromatin states at high concentrations, thereby gaining access to its most sensitive target enhancers. At lower concentrations in more posterior nuclei, Bcd is unable to access these enhancers, and therefore does not bind and activate their transcription ([Figure 7](#fig7){ref-type="fig"}). In this way, expression of these concentration-sensitive target genes is restricted to anterior regions of the embryo. The higher density of Bcd binding sites in highly concentration-sensitive target enhancers (shown in [Figure 2D](#fig2){ref-type="fig"}) suggests that these targets may require a larger number of Bcd molecules to be bound at a given time to keep them free of nucleosomes and accessible to the additional regulatory factors. We therefore provide a model for morphogen function in which the concentration thresholds in the gradient are read out molecularly at the level of chromatin accessibility, rather than through the strength of binding sites in the target sequences.

![Model for Bcd function along the AP axis.\
Bcd drives accessibility of concentration-sensitive, Bcd-dependent enhancers at high concentrations in anterior nuclei, and these sites are closed in posterior nuclei. concentration-insensitive targets remain accessible in both anterior and posterior nuclei, likely through inputs from other factors such as Zld and more open local chromatin structure with a lower nucleosome preference.](elife-28275-fig7){#fig7}

It is important to note that the discrete sensitivity classes described here were generated by Bcd binding data, and this binding is expected to occur prior to the activation of target genes and refinement of their expression domains. In our model Bcd establishes these initial patterns not by competing with its own target genes, but with default nucleosome positions in the early embryo. We predict that this initial interaction with chromatin is an essential event for establishing distinct, positionally defined patterns of gene expression. The chromatin landscapes established early by Bcd are then elaborated upon by additional patterning factors, including Bcd target genes themselves, as well as the repressor gradients proposed by Chen, *et al.* ([@bib11]) Thus, the pre-transcriptional information presented by Bcd in the form of differential binding states is refined at the level of gene expression domains both by Bcd and other transcription factors active in the early embryo.

Relationship of bicoid and Zelda at Bicoid-bound enhancers {#s3-2}
----------------------------------------------------------

The prominence of the Zld binding motif in the Bcd-bound ChIP peaks and ATAC-seq in *zld* mutants reveals that Zld also contributes to the accessibility of Bcd targets in the genome, in part at those targets that are not dependent on Bcd for their accessibility (61/1,027 peaks are dependent on both Bcd and Zld for accessibility). Zld is therefore likely to be one component that influences the accessibility and therefore the apparent in vivo affinity of the peaks that are bound by Bcd but insensitive to its local concentration ([Figure 7](#fig7){ref-type="fig"}). Indeed, it has been demonstrated that Zld can extend the effective range of the dorsal-ventral morphogen Dorsal and aid in establishing concentration thresholds and interpreting the gradient at low concentrations, while the requirement for Zld is less significant at high concentrations ([@bib46]). Previous work has also suggested that Zld contributes to activation of target genes at low concentrations of Bcd protein ([@bib70]), and a recent study demonstrated optically that in the absence of Zld, Bcd occupancy on chromatin in the posterior of the embryo is reduced ([@bib44]).

These studies, in combination with the work presented here, allow us to predict that transforming a concentration-sensitive Bcd target enhancer into a Zld dependent enhancer would increase the accessibility and therefore the sensitivity of that region in vivo. Indeed, Xu, *et al.* have previously demonstrated that adding increasing numbers of Zld sites to an inactive Bcd-bound enhancer can drive increasingly posterior gene expression ([@bib70]). The reporter construct used to demonstrate this effect (HC_45) is identified as a Concentration-Sensitive I target in our study. We posit that the increase in gene expression from this reporter observed in their work is the result of increasing the accessibility of the enhancer region. Interestingly, adding four additional Bcd sites to this reporter also activates anterior gene expression. This suggests that at high concentrations, Bcd\'s activity is similar to Zld.

Alternately, when we replace Zld sites with Bcd sites in an enhancer that drives posterior expression, the expression domain shifts to the anterior of the embryo. This demonstrates that without Zld to keep the enhancer open in posterior nuclei, activation of the reporter gene becomes entirely dependent on Bcd, effectively shifting this reporter from a concentration-insensitive to concentration-sensitive enhancer. This finding fits with both previously reported findings and the model proposed in our study. Namely, that Zld contributes to the accessibility of Bcd target genes throughout the embryo, while high levels of Bcd can drive accessibility independently and activate gene expression at a subset of targets in the anterior of the embryo.

The reduced binding by a truncated Bcd protein at the most concentration-sensitive targets indicates that Bcd does not displace nucleosomes by simply by competing for binding to genomic targets, but rather that the C-terminus of the Bcd protein is required for accessing its nucleosome-associated DNA targets. Previous work has shown that various domains of the Bcd protein are required for interactions with both co-activators and co-repressors. The N-terminus of Bcd is required for interactions with components of the Sin3A/HDAC repressor complex, and these interactions are proposed to play a role in reducing Bcd\'s transcriptional activation activity ([@bib73]; [@bib74]). Multiple Bcd domains, including the C-terminus, are required for interaction with CREB-binding protein (CBP), which has histone acetyltransferase activity ([@bib21]; [@bib22]). It is possible that in our truncated Bcd construct, this interaction with CBP is disrupted. As CBP is thought to play a role in increasing chromatin accessibility for transcription factors ([@bib10]), the loss of this interaction could lead to the reduced binding to sensitive targets that we observe in embryos with truncated Bcd. The targets that we have classified as concentration-insensitive do not depend on Bcd to establish an open chromatin state. This suggests that these sites are opened by other chromatin remodeling factors, or are inherently more likely to be nucleosome-free based on their underlying sequence.

It has previously been suggested that transcription factors can compete with nucleosomes for access to their DNA binding sites ([@bib45]; [@bib66]). This could occur through cooperative binding to nucleosome-associated enhancers: if one Bcd molecule could gain access to a binding site that was protected by a nucleosome, it could recruit additional Bcd protein molecules to bind to nearby sites and occlude nucleosome binding. This cooperativity would require a high concentration of Bcd protein, fitting with our observation that Bcd influences accessibility more strongly at high concentrations. However, our experiments with a truncated Bcd protein reveal that Bcd cannot bind to its most sensitive targets without its C-terminal domains. As many of the residues that have been implicated in cooperative binding reside in the Bcd homeodomain ([@bib8]), we would expect this truncated Bcd to bind cooperatively. This finding therefore supports a model in which Bcd is actively remodeling chromatin, either directly or more likely by interacting with chromatin remodeling factors through its C-terminus.

As a maternally supplied factor, Bcd provides one of the first cues to the break the symmetry of the embryonic body plan. Our results suggest that this symmetry breaking occurs first at the level of chromatin accessibility, as Bcd drives the opening of its most concentration-sensitive target enhancers in anterior nuclei. Another maternal factor, Zld, is proposed to act as a pioneer factor at early embryonic enhancers with a high intrinsic nucleosome barrier. By binding to these enhancers, Zld depletes them of nucleosomes and allows patterning transcription factors to bind and activate gene expression ([@bib61]). We have demonstrated here that Bcd influences the accessibility primarily of its concentration-sensitive targets, which also exhibit a high predicted nucleosome barrier ([Figure 4B](#fig4){ref-type="fig"}). This raises the possibility that Bcd may be exhibiting pioneer-like activity at high concentrations, driving accessibility of these sites prior to transcriptional activation. It is unlikely that Bcd is unique in its ability to influence the local chromatin accessibility of its targets. Recent work in mouse embryos has shown that another homeodomain transcription factor, Cdx2, influences the chromatin accessibility of its targets during posterior axial elongation ([@bib1]). It will therefore be of interest to assess whether other developmental transcription factors can drive accessibility of their genomic targets while the chromatin state of the genome is being remodeled during early development.

Materials and methods {#s4}
=====================

Model organism {#s4-1}
--------------

All reported experiments were performed on embryos from transgenic and mutant variants of the Fruit Fly *Drosophila melanogaster* (NCBI Taxon 7227).

Fly stocks and Genetics {#s4-2}
-----------------------

*bcd* mutants refers to embryos derived from *bcd^E1^* homozygous mothers. The *bcd^E1^* and *bcd^E1^ nos^L7^ tsl^4^* stocks were from the Wieschaus/Schüpbach stock collection maintained at Princeton University. *zld* mutants are embryos derived from *zelda^294^* germline clones. Zelda mutant embryos were generated from the *zld^294^* allele (kind gift of Christine Rushlow) as germline clones as described previously ([@bib4]). Uniform Bcd and Bcd^085^ transgenes were expressed in a *bcd^E1^* mutant background. Germline clones possessing only positional information from Bcd were generated by heat shocking *hsFLP; FRT82B hb^FB^ nos^BN^ tsl^4^/FRT82B tsl^4^ Ovo^D^* larvae. Germline clones lacking Bcd positional information as well were generated by heat shocking *hsFLP; FRT82B bcd^E1^ hb^FB^ nos^BN^ tsl^4^/FRT82B tsl^4^ Ovo^D^* larvae. Embryos from homozygous *eGFP-Bcd; bcd^E1^ nos^L7^ tsl^4^* mothers were used in ChIP-seq experiments to determine the impact of removing other maternal factors on Bcd binding to its targets.

All ATAC-seq experiments were performed in a *His2Av-GFP* (Bloomington) background to facilitate scoring of nuclear density.

The uBcd transformants expressed eGFP-tagged Bcd in a graded distribution in the embryo and RFP in the eyes. Transgenic flies containing the uBcd constructs were crossed into a *bcd^E1^* background. To achieve uniform Bcd expression, the uBcd flies were crossed to a stock expressing a heat shock-inducible *flippase* in a *bcd^E1^* background and the resulting larvae were heat shocked at 37**°**C. Recombination of the FRT-flanked cassette containing the *bcd* 3\'UTR and 3xP3-RFP was scored by a mosaic loss of RFP expression in the eyes. Mosaic flies were further outcrossed to *bcd^E1^* and progeny lacking the *bcd* 3\'UTR were sorted by loss of RFP expression. The resulting flies produced embryos in which the *bcd* 3\'UTR was replaced by the sqh 3\'UTR causing a uniform distribution of Bcd along the AP axis. ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"})

Transgenic constructs {#s4-3}
---------------------

The uniform Bcd constructs were generated using a pBABR plasmid containing an N-terminal GFP-tagged *bcd* cDNA in which the *bcd* 3\'UTR was replaced by the *sqh* 3\'UTR (pBABR GFP-Bcd3\'sqh) (Oliver Grimm, unpublished). This results in a loss of mRNA localization at the anterior pole of the oocyte. A sequence containing the *bcd* 3\'UTR and a 3xP3-RFP reporter flanked by FRT sites was synthesized by GenScript and cloned by Gibson Assembly into the pBABR GFP-Bcd3\'sqh plasmid. The FRT-flanked cassette was inserted between the *bcd* coding sequence and the *sqh* 3\'UTR. The *bcd* promoter was removed by digesting with AgeI and KpnI and replaced with either the *mtrm* or the *αTub67C* promoter to generate the *bcd-uBcd*, *mtrm-uBcd*, and *αTub67C-uBcd* constructs.

The GFP-Bcd^085^ truncation was generated from eGFP-Bcd ([@bib26]) in pBlueScript by amplifying with primers to create a stop codon after amino acid 179 as in the *bcd^085^* hypomorphic EMS allele ([@bib53]). The primers inserted an AvrII restriction site 3\' to the deletion site.

F Primer: 5\'-TTGtag[CCTAGG]{.ul}CCTGGATGAGAGGCGTGT-3\'

R Primer: 5\'-TCCAGG[CCTAGG]{.ul}ctaCAAGCTGGGGGGATC-3\'

The plasmid was amplified by PCR and the linear product was digested and ligated to create the Bcd^085^ truncation. The GFP-Bcd^085^ construct was digested from pBlueScript with BamHI and EcoRI and ligated into pBabr.

The uBcd and Bcd^085^ constructs were injected for site directed transgenesis into embryos from a *y,w;attp40* stock by Genetic Services (*bcd-uBcd* and *αTub67C-uBcd*) or BestGene (*mtrm-uBcd* and *Bcd^085^*) and stable transformant lines were established. The mutant cad-GAL4 reporter was injected into a *M{vas-int.Dm}ZH-2A, P{CaryP}attP2* stock by Rainbow Transgenic Flies, Inc.

The wild-type cad-GAL4 reporter (VT010589, coordinates chr2L: 20767347--20768825) was ordered from the Vienna Drosophila Resource Center (VDRC ID 205848/construct ID 210589). The mutated *cad* enhancer sequences were synthesized by GenScript, amplified using primers

F primer: 5'-[CACC]{.ul}GGCACTCAGTAGAGCA-3'

R primer: 5'-GCGACCCAAAGACCAGAATA-3'

and inserted into the pBPGUw vector ([@bib51]) by Gateway cloning using a pENTR/D-TOPO cloning kit (Thermo Fisher Cat \# K240020).

The HC_45 and HC_45.4Z sequences were taken from [@bib70]. The HC45 +4 Bcd sequence was generated by replacing the extra Zld sites in HC45.4Z with Bcd binding sites. All three sequences were synthesized by GenScript, amplified using primers

F primer: 5\'-[CACC]{.ul}TCGATTTTCTGTTGCCATTTC-3\'

R primer: 5\'- CCTGATGGCTGTCCTCTGT-3\'

and inserted into the pBPGUw vector ([@bib51]) by Gateway cloning using a pENTR/D-TOPO cloning kit.

Western blots {#s4-4}
-------------

Live embryos were dechorionated in bleach, rinsed in salt solution (NaCl with TritonX-100), and embryos at NC14 were sorted under a light microscope and flash frozen on dry ice. Western blots were performed using a using a rabbit anti-GFP antibody (Millipore Cat \# AB3080P) and mouse anti-tubulin antibody (Sigma Cat \# T9026) as a loading control. For quantification, the GFP band intensities were normalized to α-tubulin band intensities in each lane. Two biological replicates of 50 embryos were homogenized in 50 μL buffer for each genotype, and 10 μL (=10 embryos) was loaded per lane.

Western blots were used to generate an estimate of Bcd concentration in each of the uniform Bcd lines. Drocco *et al.* used western blots to measure Bcd protein accumulation in the embryo during development, and calculated the total amount of Bcd in the embryo at NC14 to be 1.5 ± 0.2×10^8^ molecules ([@bib18]). Given that the volume of the nucleus is \~1/10 (or 1/1 + 9) the volume of the cytoplasm and Bcd partitions between the nucleus and the cytoplasm at a ratio of \~4:1 ([@bib26]), we can generate a ratio of 4/4 + 9 or 0.31 for nuclear/cytoplasmic Bcd. Using this value, we can convert 1.5 ± 0.2×10^8^ molecules/embryo into 4.6 × 10^7^ molecules/nucleus at NC14. At this stage, there are 6000 nuclei at the cortex of the embryo, which would be \~7,750 Bcd molecules/nucleus if the Bcd were distributed uniformly. Additionally, optical measurements estimate a nuclear concentration of Bcd as 8 ± 1 nM and 690 Bcd molecules at the *hunchback* expression boundary (\~48% x/L) at NC14 ([@bib25]). We used these values to generate a conversion factor of 0.011594203 nM/molecule and calculate the approximate nuclear concentrations given below ([Table 6](#table6){ref-type="table"}) for each uniform Bcd line. See also [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}.

10.7554/eLife.28275.019

###### Estimated nuclear concentrations of Bcd protein in each uniform line.

  Genotype            Protein level relative to WT   Estimated number of molecules   Estimated nuclear concentration
  ------------------- ------------------------------ ------------------------------- ---------------------------------
  *bcd \> uBcd*       0.14                           1085                            12.58 nM
  *mtrm \> uBcd*      1.1                            8525                            98.84 nM
  *αTub67C \> uBcd*   2.7                            20925                           242.61 nM

Immunostaining and imaging {#s4-5}
--------------------------

Embryos of indicated genotypes were collected from 0 to 4 hr laying cages, and fixed and stained essentially as described in ([@bib19]), with rabbit anti-Bcd, guinea pig anti-Kni, and rat anti-Btd primary antibodies, followed by fluorophore-conjugated secondary antibodies Alexa-488 (guinea pig), Alexa-568 (rat), and Alexa-647 (rabbit) from Invitrogen. Stained embryos were imaged on a Leica SP5 laser-scanning confocal microscope.

Live imaging and image analysis {#s4-6}
-------------------------------

Dechorionated embryos of the indicated genotypes were mounted on coverslips overlaid with halocarbon oil and imaged in the mid-sagittal plane on a Leica SP5 laser scanning confocal microscope. Image analysis was performed in MATLAB (<http://www.mathworks.com>). GFP intensity along the dorsal profile of each embryo was extracted for each frame of the live movies in nuclear cycle 14. The frame with the highest overall intensity in each movie was plotted.

Bicoid Homeodomain expression and protein purification {#s4-7}
------------------------------------------------------

A cDNA coding for amino acids 89--154 of the Bcd protein (including the homeodomain) as described in ([@bib9]) using primers

5'-CAGCCAcatatgCTTTTCGATGAGCGAACG-3'

5'-GAGCCCggatcccta[AGCGTAATCTGGAACATCGTATGGGTA]{.ul}CTGTTTCATACCCGGCGA-3'

to add a C-terminal HA epitope tag (underlined) and NdeI and BamHI sites (lowercase).

The PCR product was cloned into the pET-15b plasmid using NdeI and BamHI, which contains an N-terminal 6xHis tag and T7 promoter, to make plasmid pET-15B-BcdHD. Expression was induced in BL21 (DE3) pLysS *E. coli* cells using 2 mM IPTG. The protein was purified by affinity chromatography using HisPur Cobalt Resin (Fisher Scientific Cat \# 89965) followed by ion exchange chromatography with SP Sepharose Fast Flow resin (GE Healthcare Cat \#17-0729-01).

EMSAs and K~d~calculations {#s4-8}
--------------------------

EMSAs were performed using purified Bcd homeodomain and biotin-labeled DNA probes were designed to span \~200 bp in the maximal peak region of Bcd-bound peaks identified by ChIP and corresponding to previously characterized enhancers (see [Table 7](#table7){ref-type="table"}). Effective K~d~ values for each enhancer probe were calculated using the ratio of total shifted probe to free probe.

10.7554/eLife.28275.020

###### Primer sequences for EMSA probes.

  Primers                         Sequence (5\'- \> 3\')
  -------------- ---------------- ---------------------------------
  hbP2 probe F   Forward primer   /bio/GTCAAGGGATTAGATGGGCA
  hbP2 probe R   Reverse primer   /bio/GTCGACTCCTGACCAACGTA
  kni post F     Forward primer   /bio/AGAAAAAATGAGAACAATGTGAC
  kni post R     Reverse primer   /bio/AGCCAGCGATTTCGTTACCT
  kni ant F      Forward primer   /bio/ACAACACCGACCCGTAATCC
  kni ant R      Reverse primer   /bio/GTCATGTTGGCTAATCTGGC
  kr ant F       Forward primer   /bio/CAGAAAAGAAAAAGTGTAACGCC
  Kr ant R       Reverse primer   /bio/GCGAAAAAACGCGTCGCGCT
  otd intron F   Forward primer   /bio/ATCGTTCCTTGCGGTTTAAT
  otd intron R   Reverse primer   /bio/AGAACAGGACAAAGGGAATTTAATC
  otd early F    Forward primer   /bio/CTCGCCTCGCGTGCGACATT
  otd early R    Reverse primer   /bio/CCTGCGGCAGGACTTCACTT
  btd F          Forward primer   /bio/ACGAAGTCAAAACTTTTCCA
  btd R          Reverse primer   /bio/AGCTAAGAGATCTCAACCAAC
  gt −3 F        Forward primer   /bio/TTACAACTGCCCATTCAGGG
  gt −3 R        Reverse primer   /bio/GAAGGGCTCGGGTTCGG
  gt −10 F       Forward primer   /bio/AGATCCAGGCGAGCACTTGA
  gt −10 R       Reverse primer   /bio/TTAAATTAAAATGTCGCAGGAAGGCG

ChIP-seq and data analysis {#s4-9}
--------------------------

### Sample collection {#s4-9-1}

*Drosophila* embryos were collected from 0 to 4 hr laying cages, dechorionated in bleach and crosslinked with 180 mL 20% paraformaldehyde in 2 ml PBS + 0.5% Triton X-100 and 6 mL Heptane for 15 min. Crosslinking was quenched with 125 mM Glycine in PBS + 0.5% Triton X-100. Fixed embryos were visually staged and sorted using a dissecting microscope, and all experimental replicates consisted of 200 embryos in nuclear cycle 14. Chromatin immunoprecipitation was performed with an anti-GFP antibody (Millipore) in embryos expressing GFP-tagged Bcd either in a wild-type graded distribution (*eGFP-Bcd;;bcd^E1^* \[n = 8 biological replicates\], *eGFP-Bcd;;bcd^E1^ nos^L7^ tsl^4^* \[n = 2 biological replicates\] and *eGFP-Bcd^085^;bcd^E1^* \[n = 3 biological replicates\]) or uniformly (*GFP-uBcd;;bcd^E1^* \[n = 3 biological replicates for each uniform line\]). Sequencing libraries were prepared using the NEBNext ChIP-seq Library Prep master mix kit and sequenced as described in ([@bib4]; [@bib18]).

### Defining a peak list {#s4-9-2}

Barcode split sequencing files were mapped to *Drosophila melanogaster* genome assembly BDGP R5/dm3 using Bowtie2 ([@bib26]; [@bib35]) using default parameters. To generate a conservative, high-confidence list of Bcd-bound peaks, peaks were called on each replicate of wild-type and uniform Bcd ChIP-seq data using MACS2 ([@bib25]; [@bib72]) with settings -p 1e-3 \--to-large \--nomodel \--shiftsize 130 for wild-type samples and -p 0.000001 \--slocal 5000 \--llocal 50000 \--keep-dup all for uBcd samples. The most reproducible peaks from each genotype were selected using an irreproducible discovery rate (IDR) of 1% ([@bib19]; [@bib34]; [@bib40]). Given evidence that highly transcribed (i.e., highly accessible) regions often give false positive results in ChIP experiments ([@bib9]; [@bib63]), we used our ATAC-seq data to filter our ChIP-seq peaks. We compared the number of CPM-normalized ATAC-seq reads to ChIP-seq reads in each peak, and performed permutation tests (n = 1,000) to determine the probability of selecting open regions of the genome at random that had higher ATAC-seq counts (i.e., regions that were more accessible) than the ATAC-seq counts in the Bcd ChIP peaks. We determined that at a ratio of 5.4 ATAC-seq/ChIP-seq counts, 95% of the ChIP peaks (permutation test p value = 0.05) were no more open than a random selection of open regions. We filtered out the remaining ChIP peaks with ATAC/ChIP ratios above 5.4, as these peaks are more likely to correspond to highly transcribed open regions where most false positive signals can be found. We then chose the peaks that were common to wild-type and uniform Bcd embryos, which resulted in a list of 1,027 Bcd-bound peak regions. The number of peaks at each step of this filtering is shown in [Table 1](#table1){ref-type="table"}.

### Comparing binding between uniform bcd levels {#s4-9-3}

Mapped BAM files were imported into R as GenomicRanges objects ([@bib36]), filtering out reads with map quality scores below 30. Significant differences between the uBcd levels were assessed on a pairwise basis using edgeR ([@bib54]) in the 1027 pre-defined peak plus 50,000 additional non-peak noise regions selected from the dm3 genome.

### Data normalization and display {#s4-9-4}

Sequencing data was z-score normalized for display in heatmaps. Sequencing read count coverage was calculated for 10 base pair windows across the genome, and the mean counts per million reads were determined in each ChIP peak, as well as the additional noise peaks. Z-scores were computed for each peak using$$z = \frac{CPM - \mu}{\sigma}$$

where$\mu$ = mean CPM in noise peaks and $\sigma$ = standard deviation of CPM in noise peaks.

ATAC-seq and data analysis {#s4-12}
--------------------------

### Sample collection {#s4-12-1}

Live embryos expressing a histone (H2Av)-GFP or RFP construct were individually staged on an epifluorescence microscope in halocarbon oil. After the onset of nuclear cycle 14, single embryos were dechorionated in bleach and macerated in cold lysis buffer at t = 12 min into NC14. Samples were pelleted in lysis buffer at 4**°**C (3000 rpm for 10 min), buffer was removed, and the embryo pellet was flash frozen on dry ice. Frozen pellets were resuspended in Nextera Tagment DNA Buffer +Enzyme and incubated at 37**°**C for 30 min shaking at 800 rpm. Tagged DNA was purified using a Qiagen Minelute column and eluted in 10 μL. Barcoded sequencing libraries were generated by PCR amplifying the purified DNA using the Nextera DNA Sample Prep kit. Paired-end sequencing was performed on six samples per genotype (n = 5 samples for *bcd^E1^)* by the Lewis Sigler Institute for Integrative Genomics Sequencing Core Facility on an Illumina HiSeq 2500.

### Data processing {#s4-12-2}

Initial processing of the data was performed essentially as described in ([@bib5]). Sequencing files were barcode split and adaptors were trimmed using TrimGalore. Trimmed reads were mapped to the BDGP R5/dm3 genome assembly using BWA ([@bib38]) with default parameters. Optical and PCR duplicates were marked using Picard Tools MarkDuplicates (<https://broadinstitute.github.io/picard/>). Mapped reads were filtered using samtools ([@bib39]) to remove reads with a map quality score ≤30, unmapped reads, improperly paired reads, and duplicate reads. To distinguish reads corresponding to open chromatin reads from nucleosome protected reads, the size of the ATAC-seq fragments were fit to the sum of an exponential and Gaussian distribution as described in ([@bib6]). We used a fragment size cutoff of ≤100 bp to identify fragments originating from open chromatin. Filtered open reads were imported into R as GenomicRanges objects.

### Peak calling {#s4-12-3}

Regions of open chromatin at NC14 +12 min were determined by calling peaks on the merged open chromatin reads from wild-type replicates using Zinba ([@bib52]) with the parameters:

input = \'none\', winSize = 300, offset = 50, extension = 65, selectmodel = FALSE, formula = exp_count \~ exp_cnvwin_log + align_perc, formulaE = exp_count \~ exp_cnvwin_log + align_perc, formulaZ = exp_count \~ align_perc, FDR = TRUE, threshold = 0.05, winGap = 0, cnvWinSize = 2.5E + 4, refinepeaks = TRUE.

### Nucleosome positioning {#s4-12-4}

Nucleosome positioning was determined in samples from all genotypes using NucleoATAC ([@bib56]), with default settings. Peak regions used for NucleoATAC were open chromatin peaks from Zinba combined with the Bcd ChIP peaks and widened to 2500 bp centered over the peak maxima. This combined peak list was then reduced and used as NucleoATAC input. For each genotype, BAM files from ATAC-seq were merged and used as input for NucleoATAC.

### Differential Accessibility between Wild-Type, bcd^E1^, and zld^-^ Embryos {#s4-12-5}

EdgeR was used to determine significant differences in accessibility between different genotypes, with an exact test FDR ≤ 0.05 used as the significance cutoff. For edgeR comparisons, the ATAC-seq peaks called by Zinba from wild-type embryos at NC14 +12 min were combined with Bcd ChIP-seq peaks resized to 300 bp centered around the peak summit and 25,000 background regions. The background regions were generated by extending each of the ATAC open peaks to 10 kb and subtracting them from the dm3 genome assembly. The remaining non-peak regions were then sampled randomly 25,000 times and widened to reflect the distribution of sizes in the ATAC-seq peaks. Bcd- or Zld-dependent peaks were those peaks identified as having reduced accessibility in *bcd^E1^* or *zld^--^* embyos. A summary of the differential accessibility in the ATAC-seq vs. Bcd ChIP-seq peaks is shown in [Table 4](#table4){ref-type="table"}.

To measure differential accessibility of Bcd motifs between wild-type and *bcd^E1^* mutant embryos, the positions of Bcd motifs within ChIP-seq peaks were found, and ATAC-seq accessibility scores were calculated for the 10 bp window containing the midpoint of each Bcd motif. Scores for all motifs within a single peak were averaged prior to plotting. Motifs were found using the 'strong' Bcd position weight matrix via the R function 'matchPWM' in the Biostrings package with an 80% match threshold.

To estimate the overlap between nucleosomes and Bcd motifs, predicted nucleosome dyad centers from NucleoATAC were widened to 160 bp and motifs overlapping these intervals were scored as 'nucleosome associated'. Motifs not overlapping widened nucleosome intervals were scored as 'open'. The fraction of open Bcd motifs per peak was calculated by dividing the number of open Bcd motifs by the total number of encoded Bcd motifs over each peak.

Data normalization and display {#s4-13}
------------------------------

For each genotype, BAM-formatted ATAC-seq reads for each replicate, filtered by quality and duplicates removed as described above, were merged into a single file. Coverage was calculated from these BAM files in 10 bp windows in the dm3 genome assembly. This coverage was then normalized by counts per million reads. The genome coverage in 2 kb regions flanking Bcd ChIP peaks was then z-score normalized as described above. The z-score values are displayed as heatmaps of open chromatin displayed in [Figure 3A and B](#fig3){ref-type="fig"}. Heatmaps are plotted in an order of decreasing accessibility z score in wild-type embryos.

Predicted dyad centers from NucleoATAC were widened to 147 bp to model nucleosome positions. Occupancy scores from NulcleoATAC in the 147 bp nucleosomes were computed in 10 bp windows across the dm3 genome assembly. Occupancy scores overlapping Bcd ChIP peaks are plotted in the heatmaps in [Figure 4A and B](#fig4){ref-type="fig"}. Nucleosome heatmaps are plotted in the same order as open chromatin heatmaps, by decreasing accessibility z score in wild-type embryos.

[Supplementary file 1](#supp1){ref-type="supplementary-material"} shows the genomic (BDGP Release 5/dm3) coordinates of Bcd-bound peaks identified by ChIP-seq as described in [Table 1](#table1){ref-type="table"}. Additional columns indicate the nearest gene to the peak that shows maternal or zygotic expression in the embryo ([@bib4]) and classifications of each peak as Bcd or Zld dependent for accessibility (determined by ATAC-seq) and their sensitivity group classifications (determined by ChIP-seq). The tileID column gives the name of each Vienna Tile-GAL4 construct (if any) that overlaps with each peak, and the HC_ID column indicates reporter constructs from ([@bib11]) that overlap with each peak.

In situ hybridizations and Cad-GAL4 reporters {#s4-14}
---------------------------------------------

The GAL4 coding sequence was amplified from a genomic DNA preparation generated from a *Drosophila* stock carrying a GAL4 reporter, using primers 5'- TGCGATATTTGCCGACTTA-3' and 5'-[TGTAATACGACTCACTATAG]{.ul}GGAACATCCCTGTAGTGATTCCA-3'. The amplified sequence was used as a template in the MEGAscript T7 Transcription Kit (ThermoFisher Cat. \#AM1334) to with digoxygenin-labeled UTP to generate an anti-GAL4 RNA probe. In situ hybridizations were performed according to standard protocols.

Accession numbers {#s4-15}
-----------------

The Gene Expression Omnibus (GEO) accession number for this study is GSE86966.
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###### Bicoid ChIP-seq Peak Regions and Functional Annotation

The 1027 peak regions as determined by ChIP-seq for Bcd are listed with functional categorizations described in the text. Column names are indicated in the first row. Genomic coordinates of peak binding regions were determined against the dm3 build of the *Drosophila melanogaster* genome, and are reported in columns 1--4 (chromosome, start, end, strand). The nearest zygotically active gene (including maternal and zygotic genes) is listed in column 5 (nearest.mz). Columns 6 and 7 indicate whether a Bcd ChIP-seq peak was determined to require either Bcd (column 6) or Zld (column 7) for chromatin accessibility as determined by ATAC seq. Columns 8--11 indicate the concentration-dependent binding class determined for each peak. Column 12 indicates the identification number of Vienna Tiles that were found to uniquely overlap with a Bcd ChIP-seq peak. Column 13 indicates the identification number of DNA fragments reported in [@bib11] overlapping with Bcd ChIP-seq peaks from this study. Column 14 indicates the Bcd ChIP-seq peaks that were found to overlap with Zld ChIP-seq peaks reported in [@bib27].

10.7554/eLife.28275.022

Major datasets {#s7}
--------------

The following dataset was generated:

Hannon CEBlythe SAWieschaus EF2016Concentration dependent binding states of the Bicoid Homeodomain Protein<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86966>Publicly available at the NCBI Gene Expression Omnibus (accession no. GSE86966)
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Decision letter

Espinosa

Joaquín M

Reviewing Editor

University of Colorado School of Medicine

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Concentration Dependent Chromatin States Induced by the Bicoid Morphogen Gradient\" for consideration by *eLife*. Your article has been favorably evaluated by James Manley (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The manuscript shows a strong dataset demonstrating that Bicoid influences chromatin accessibility in a concentration-dependent manner, and that Bcd can act as a pioneer factor when at high concentrations. Using fly embryos engineered to uniformly express high, medium, and low levels of Bcd protein, the authors identified four classes of Bcd bound regions, with Concentration-Sensitive I and II classes bound only by high and high/medium levels of Bcd, respectively, driving anterior expression of candidate enhancer fragments, enriched for Bcd motifs, and highly represented in Bcd-dependent chromatin accessibility regions. Concentration-Sensitive III class peaks were bound stronger by high/medium levels of Bcd but lower by low levels of Bcd, driving broad expression of candidate enhancer fragments, not enriched for the transcription factor Zelda (Zld) or Bcd motifs, and not quite dependent on Bcd for chromatin accessibility. Concentration-Insensitive class peaks were bound equally well by all levels of Bcd, driving posterior expression of candidate enhancer fragments, highly enriched for Zld motifs, and not dependent on Bcd for chromatin accessibility. The authors found that the presence and/or the strength of Bcd motifs do not account for in vivo sensitivity to Bcd concentration, as predicted by the binding site affinity threshold model for morphogen function. Rather, the Bcd morphogen gradient is read at the level of chromatin accessibility, established at Bcd concentration-sensitive targets primarily and perhaps even independently by high levels of Bcd, and at concentration-insensitive targets by factors like Zld. The authors further demonstrated using a C-terminus truncated Bcd that the ability of high levels of Bcd to drive chromatin accessibility at concentration-sensitive targets is likely through co-factor recruitment, rather than Bcd cooperative binding. Finally, they turn a Zld dependent target enhancer into a Bcd high level target by changing Zld binding sites into Bcd binding sites thereby increasing the number of Bcd binding sites, and suggest that high levels of Bcd can confer chromatin accessibility.

Overall, the paper supports the model put forth, whereby Bcd itself, acting through different classes of genomic binding sites differentially sensitive of Bcd concentration, can create a regulatory logic that delivers spatio-specific regulation of its targets.

Although the study was well designed and performed, the reviewers ask that the authors address several criticisms as outlined below.

1\) The manuscript was difficult to follow at times. For Bcd aficionados it may be easier, but for the more general audience of *eLife*, it might be difficult to read, not only because of the many typos, but the jargon and flow. Examples are: a) What does \"strong Bcd gradient\" mean? b) Introduction, third paragraph, first sentence: The two phrases seem disconnected. Also, the last sentence of this paragraph could also use some word changes to be more logical; perhaps \"Therefore\" instead of \"However\" would flow better. c) A transition is missing between the last two paragraphs of the Introduction. Why is the employed approach better than computational predictions and in vitro measurements? The logic is not obvious. d) Introduction, last paragraph: The use of the word \"enhancer\" is vague and somewhat misleading. The data reveal distinct classes of Bcd targets not necessarily enhancers. However, further down when referring to the model, it seems appropriate to use \"target enhancers.\"

2\) First section in Results is titled: \"Bicoid target gene...other maternal factors, but is physical interaction is not". Change \"maternal\" to \"patterning\" since Bcd binding is changed in zelda mutants (Xu et al., 2014).

3\) With regard to \"enhancers whose expression patterns span broadly across the AP axis\" -- where is the data to support this statement. How many of the 1027 Bcd peaks do these enhancers you speak of comprise -- 10 or 100? It is unclear if the following section, are the three specific targets supposed to represent these enhancers? It is not clear because the transition is poor between these paragraphs. Nevertheless, please show the data that led to this conclusion that peaks \"overall associate with enhancers\[...\]\"

4\) The terminology used in the Results (and elsewhere) is incorrect. \"the *kni* posterior enhancer is not expressed\" -- enhancers are not expressed, genes are expressed; enhancers drive expression. By the way, which enhancer is driving the strong expression seen in the *bcd hb nos tsl* embryo in [Figure 1A](#fig1){ref-type="fig"} bottom right? Why is there such a discrepancy between this embryo and the one shown in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} where expression appears lower? Please sort this out.

5\) In general, the term \"enhancer\" is used too loosely in this paper and it is advised that the authors change this. For example, in the last sentence of the second paragraph of the subsection "Bcd binding to genomic targets is concentration dependent" the use of \"enhancer\" (twice) is premature because it isn\'t until the following paragraph where a correlation between Bcd peaks and known enhancers is discussed.

6\) In the third paragraph of the subsection "Bcd binding to genomic targets is concentration dependent", of the 163 Vienna enhancers that are active in stage 4-6, how many are expressed in a discrete AP domain? I could not find this information and it should be included. Also, why don\'t all 163 candidate enhancers overlap with a Bcd peak if the 293 overlap with at least one Bcd peak. Also, it is unclear how \"77.2%\" was derived. 163/293 = 55.6. Please clarify.

7\) The statement, \"we find no evidence that the Bcd sensitivity classes are predominantly defined by repressive interactions.\" It is worrysome that the authors are making a sweeping statement when there are clearly Concentration-Sensitive I enhancers that bind repressors, in addition to those shown by Chen et al. (2012). For example, anterior *Gt* and *Kr* are not in the same expression domain, which is not in align with the statement in the last paragraph of the subsection "Bcd binding to genomic targets is concentration dependent", and *Kr* was found enriched in Concentration-Sensitive I peaks that include the *Gt* anterior enhancer. Though it is brave to conclude from the data presented that Bcd sensitivity class gene expression domains are not defined by repressors, it seems dangerous because so many AP gene domains that have been well studied are defined by repressor interactions. Is it possible that enrichment for specific repressors was not seen because your group of peaks contains peaks that are not real Bcd target enhancers and thus the real ones get diluted out?

8\) In [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"} and B that Concentration-Sensitive III peaks are enriched in pol II binding and the Dref motif, which is a type of promoter element. Also, it is not clear why the BDTNP Bcd peaks were not enriched in Concentration-Sensitive III peaks even though they are in this study. I\'m somewhat confused by these peaks -- on the one had they appear to be at promoters (versus enhancers), which might bind Bcd promiscuously because they are so open, but on the other hand they have Bcd binding sites. At any rate, it would be important to show more examples of the genes associated with Concentration-Sensitive III peaks and what happens to their expression in bcd mutants, starting with the two mentioned, *cnc* and *hkb*. Also, importantly, it should be shown how many of the peaks in each class are near a TSS (within 500 bp). Do they differ?

9\) Text in the first paragraph of the subsection "Sequence composition of ChIP sensitivity classes does not account for in vivo sensitivity to Bcd concentration" is confusing. The authors say their results are not in agreement with those of Ochoa-Espinosa et al. (2005) study, but then in the next paragraph they say their results confirm theirs. Please rewrite for clarity.

10\) When demonstrating the relationship between Zld and Bcd at Bcd-bound regions, the authors claimed that \"Zld-dependent peaks are distributed across each sensitivity class determined by ChIP, with no particular class being significantly more Zld dependent,\" thus Zld \"is unlikely to determine the differential concentration sensitivity of Bcd peaks as a whole.\" This should be examined more closely. How many of the 855 Bcd peaks that overlap with ATAC open regions overlap with Zld binding? How many of the 402 Bcd peaks with reduced accessibility in *zld-* overlap with Zld binding? How many ATAC-seq peaks overlap with Zld binding? The authors are advised to show Zld binding, Zld motifs, and Bcd motifs in [Figure 3](#fig3){ref-type="fig"}, and/or provide additional analysis separating the four classes into those bound by Zld and not bound by/bound by low levels of Zld. Does the conclusion change, e.g., is any Bcd peak class significantly more Zld dependent? If so, this must be added.

11\) Structure function studies (protein deletion mutant here) are often difficult to assess because it is unclear whether the structure, and thus function, of the remaining protein (in this case the homeodomain), not just its presence, is unchanged, which is beyond the scope of this experiment. Therefore, the authors should qualify their conclusion by adding something like \"assuming the structure of the homeodomain remains completely intact...\"

12\) The authors showed that a Concentration-Insensitive target caudal (cad), whose chromatin accessibility is Zld-dependent and Bcd-independent, can be converted to a Bcd concentration-sensitive target at anterior region by mutating Zld motifs into Bcd motifs. The authors reasoned that high Bcd levels in anterior regions conferred chromatin accessibility to the transgene. If Bcd-dependent chromatin accessibility at regions with high levels of Bcd is the key to its target expression, the authors should provide additional data to show that Bcd binds stronger to Cad (Zld-\>Bcd)-GAL4 than to Cad-GAL4 in both wt and *zld-* embryos; 2) that accessibility increases when adding Bcd sites (in the absence of Zld sites); and 3) though elaborate, adding Bcd sites to HC-45 instead of Zld sites should render the enhancer active if Bcd can pioneer chromatin.

13\) Discussion of model in [Figure 7](#fig7){ref-type="fig"}. The idea that in regions where morphogen levels are low, Zld is required to boost activity has been proposed for both Dl and Bcd (Nien et al., 2011). Likewise, that morphogens at high levels can access and activate their high-level targets mostly on their own has also been discussed (same paper). This study corroborates and advances those ideas very nicely, and this should be mentioned.

14\) The authors should move the last sentence of the paper "This may be a common property of developmental transcription factors that must gain early access *to* their target enhancers while the chromatin state of the genome is being remodeled during large scale transitions in the gene regulatory landscape." to the Abstract.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Concentration Dependent Chromatin States Induced by the Bicoid Morphogen Gradient\" for further consideration at *eLife*. Your revised article has been favorably evaluated by James Manley (Senior Editor), a Reviewing Editor, and 1 reviewer.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The authors have satisfactorily addressed reviewer concerns. The efforts made to address further experiments (especially those suggested for the cad reporter) were greatly appreciated.

Answers to author questions are answered below:

1\) Regarding the Kni stainings: We prefer to use the Kni stainings from the first experiment in [Figure 1](#fig1){ref-type="fig"}, because that experiment also utilized the same patterning markers (e. g., Btd) used in the other genotypes of the figure. We could move the Supplementary experiment to the main [Figure 1](#fig1){ref-type="fig"}, but would prefer to keep it in the Supplement. We have added sentences to the text and to the figure legend to point the reader to the more supplementary material.

Reviewer\'s answer: Yes, please keep it in the supplement.

2\) Regarding the repressor binding: However, we agree that the data are not entirely clear, and difficult to interpret. Overall we agree that this analysis does not advance the concepts in the manuscript. We did not make it a main figure in the paper for this reason, and one possibility would be to remove the figure and corresponding argument entirely from the last paragraph of the subsection "Bcd binding to genomic targets is concentration dependent". We would appreciate advice from the reviewers on this point.

Reviewer\'s answer: Please delete the corresponding argument from the last paragraph of the subsection "Bcd binding to genomic targets is concentration dependent", rather than keeping the new paragraph because it isn\'t much better with the single repressor focus.

3\) Regarding the assays on cad and HC45 reporters: The major limitation to measuring chromatin accessibility or performing ChIP on reporter constructs (as suggested in experiments 1 and 2 for our cad reporters) is that the measurements must be able to distinguish between the transgenic (reporter) and endogenous (wild-type) copies of the regulatory element in question.

Reviewer\'s answer: While it is possible to distinguish transgenic from endogenous enhancers by having one primer in the reporter sequence (GAL4), which is likely within ChIPed fragments, and one inside the enhancer (as in Xu et al., 2014 for Bcd ChIP on HC45), it is not necessary pursuing this venue at this point.

With regard to the new HC45 data, the discussion about endogenous HC45 being accessible whether active or not and with or without Zld or Bcd is interesting, though it is formerly possible that local chromatin at the transgene is not behaving the same way as endogenous. Reviewers recommend having this data as a supplemental figure.

10.7554/eLife.28275.026

Author response

> \[...\] Although the study was well designed and performed, the reviewers ask that the authors address several criticisms as outlined below.
>
> 1\) The manuscript was difficult to follow at times. For Bcd aficionados it may be easier, but for the more general audience of eLife, it might be difficult to read, not only because of the many typos, but the jargon and flow. Examples are: a) What does \"strong Bcd gradient\" mean? b) Introduction, third paragraph, first sentence: The two phrases seem disconnected. Also, the last sentence of this paragraph could also use some word changes to be more logical; perhaps \"Therefore\" instead of \"However\" would flow better. c) A transition is missing between the last two paragraphs of the Introduction. Why is the employed approach better than computational predictions and in vitro measurements? The logic is not obvious. d) Introduction, last paragraph: The use of the word \"enhancer\" is vague and somewhat misleading. The data reveal distinct classes of Bcd targets not necessarily enhancers. However, further down when referring to the model, it seems appropriate to use \"target enhancers.\"

We have made changes throughout the revised manuscript (including those specifically listed in the point above) to make the manuscript more readable and easier to follow.

> 2\) First section in Results is titled: \"Bicoid target gene...other maternal factors, but is physical interaction is not". Change \"maternal\" to \"patterning\" since Bcd binding is changed in zelda mutants (Xu et al., 2014).

This wording has been changed to follow the suggestions of the reviewers.

> 3\) With regard to \"enhancers whose expression patterns span broadly across the AP axis\" -- where is the data to support this statement. How many of the 1027 Bcd peaks do these enhancers you speak of comprise -- 10 or 100? It is unclear if the following section, are the three specific targets supposed to represent these enhancers? It is not clear because the transition is poor between these paragraphs. Nevertheless, please show the data that led to this conclusion that peaks \"overall associate with enhancers...\"

The description of expression patterns that span broadly across the AP axis was meant to refer to the 66 previously identified Bcd-dependent enhancers that overlap with our ChIP-seq peaks. However, upon re-reading this was understandably confusing. We have re-written this section for clarity.

> 4\) The terminology used in the Results (and elsewhere) is incorrect. \"the kni posterior enhancer is not expressed\" -- enhancers are not expressed, genes are expressed; enhancers drive expression. By the way, which enhancer is driving the strong expression seen in the bcd hb nos tsl embryo in [Figure 1A](#fig1){ref-type="fig"} bottom right? Why is there such a discrepancy between this embryo and the one shown in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} where expression appears lower? Please sort this out.

The embryos of different genotypes in [Figure 1A](#fig1){ref-type="fig"} are from different stainings, and compiled over a \~six month period as the genotypes became available. Although stained with identical protocols and antibodies, they were intended to compare spatial patterns of expression. They are not directly quantitatively comparable. In [Author response image 1](#respfig1){ref-type="fig"} we have included images of four *bcd hb nos tsl* embryos stained for Kni from the experiment shown in [Figure 1](#fig1){ref-type="fig"}, with the embryo used in the figure outlined in red. We have also included a wild-type embryo stained in parallel (though in a separate tube).

![](elife-28275-resp-fig1){#respfig1}

We attempted to choose a representative image for this genotype in [Figure 1](#fig1){ref-type="fig"}. However, as is evident here, the *kni* expression in this experiment is variable and the levels in some cases were higher than the background levels in the separately stained wild-type controls. This is perhaps due to the small number of germ line clone derived embryos *bcd hb nos tsl* stained in the tube.

To address this issue, we therefore repeated this experiment to allow for more quantitative comparisons of *kni* expression, simultaneously staining all genotypes (wild-type, *hb nos tsl*, and *bcd hb nos tsl*) in the same experiment, mixed in a single tube. In the original manuscript, we presented this data as a supplement to [Figure 1](#fig1){ref-type="fig"}, and quantified with a quantification of *kni* expression along the AP axis. These data clearly show that *kni* expression is reduced to low levels in the absence of Bcd, supporting the possibility that Bcd binding to the posterior *kni* enhancer is essential for the expression it drives.

We prefer to use the Kni stainings from the first experiment in [Figure 1](#fig1){ref-type="fig"}, because that experiment also utilized the same patterning markers (e.g., Btd) used in the other genotypes of the figure. We could move the supplementary experiment to the main [Figure 1](#fig1){ref-type="fig"}, but would prefer to keep it in the supplement. We have added sentences to the text and to the figure legend to point the reader to the more supplementary material.

> 5\) In general, the term \"enhancer\" is used too loosely in this paper and it is advised that the authors change this. For example, in the last sentence of the second paragraph of the subsection "Bcd binding to genomic targets is concentration dependent" the use of \"enhancer\" (twice) is premature because it isn\'t until the following paragraph where a correlation between Bcd peaks and known enhancers is discussed.

We have changed our use of \"enhancer\" throughout the revised manuscript in instances where it was used prematurely or inappropriately.

> 6\) In the third paragraph of the subsection "Bcd binding to genomic targets is concentration dependent", of the 163 Vienna enhancers that are active in stage 4-6, how many are expressed in a discrete AP domain? I could not find this information and it should be included. Also, why don\'t all 163 candidate enhancers overlap with a Bcd peak if the 293 overlap with at least one Bcd peak. Also, it is unclear how \"77.2%\" was derived. 163/293 = 55.6. Please clarify.

All 163 candidate enhancers do overlap with Bicoid peaks. But in some cases, more than one Vienna Tile overlaps with a single peak, and in other cases a single Tile overlaps with more than one Bcd peak. The correlation is not one-to-one, so the 163 enhancers only overlap with 151 total Bcd peaks, even though they all overlap with at least one.

[Author response image 2](#respfig2){ref-type="fig"} is a screenshot from the UCSC genome browser near *gt*, illustrating the issue of multiple overlaps. Here we see that while VT55790 and VT55792 each overlap a single Bcd peak, that same Bcd peak overlaps with two tiles. The Bcd peak furthest from *gt*, however, overlaps with only one tile, VT55795. VT55790 and VT55792 were therefore excluded from the plot in [Figure 2B](#fig2){ref-type="fig"}, as the expression patterns that they drive cannot be connected unambiguously to a single Bcd peak.
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The differences in Bcd peak number and Vienna Tile number are shown in [Table 2](#table2){ref-type="table"}, which is now referred to in the text of the manuscript and should clarify this issue. This table has also been expanded to include the number of single overlaps. Additionally, we returned to the Fly Enhancer database and visually scored the number of Tiles that drive expression in an AP pattern in blastoderm embryos. This has also been added to [Table 2](#table2){ref-type="table"}.

The correct number of Bcd peaks that do not correspond to any enhancer candidates in the Fly Enhancer collection is 793 (1,027-234), or 77.2%. The reference to 876 non-overlapping in the text is the sum of the peaks not represented as Tiles \[793\] + peaks overlapping with Tiles active later in development \[42\] + the peaks overlapping with inactive Tiles \[41\]. We thank the reviewers for pointing out the confusion that allowed us to detect and correct this error has been corrected in the manuscript.

> 7\) The statement, \"we find no evidence that the Bcd sensitivity classes are predominantly defined by repressive interactions.\" It is worrysome that the authors are making a sweeping statement when there are clearly Concentration-Sensitive I enhancers that bind repressors, in addition to those shown by Chen et al. (2012). For example, anterior Gt and Kr are not in the same expression domain, which is not in align with the statement in the last paragraph of the subsection "Bcd binding to genomic targets is concentration dependent", and Kr was found enriched in Concentration-Sensitive I peaks that include the Gt anterior enhancer. Though it is brave to conclude from the data presented that Bcd sensitivity class gene expression domains are not defined by repressors, it seems dangerous because so many AP gene domains that have been well studied are defined by repressor interactions. Is it possible that enrichment for specific repressors was not seen because your group of peaks contains peaks that are not real Bcd target enhancers and thus the real ones get diluted out?

We included this analysis in an attempt to address the Chen 2012 model that repressors define the expression domains of Bcd target genes. The data in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} suggest that while repressors interact with Bcd targets in each class, it is not clear from the binding data that these repressors determine the concentration sensitivity of the Bcd ChIP classes. If, for example, Runt were responsible for setting the posterior boundaries of anterior Bcd targets, we would expect enrichment for Runt binding in the Concentration-Sensitive I and II classes, which we do not observe. That was the point we were trying to make. However, we agree that the data are not entirely clear, and difficult to interpret. Overall we agree that this analysis does not advance the concepts in the manuscript. We did not make it a main figure in the paper for this reason, and one possibility would be to remove the figure and corresponding argument entirely from the revised manuscript. We would delete this text in the last paragraph of the subsection "Bcd binding to genomic targets is concentration dependent". We would appreciate advice from the reviewers on this point.

> 8\) In [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"} and B that Concentration-Sensitive III peaks are enriched in pol II binding and the Dref motif, which is a type of promoter element. Also, it is not clear why the BDTNP Bcd peaks were not enriched in Concentration-Sensitive III peaks even though they are in this study. I\'m somewhat confused by these peaks -- on the one had they appear to be at promoters (versus enhancers), which might bind Bcd promiscuously because they are so open, but on the other hand they have Bcd binding sites. At any rate, it would be important to show more examples of the genes associated with Concentration-Sensitive III peaks and what happens to their expression in bcd mutants, starting with the two mentioned, cnc and hkb. Also, importantly, it should be shown how many of the peaks in each class are near a TSS (within 500 bp). Do they differ?

There are several possible reasons why our Bcd ChIP peak list differs from the BDTNP peaks.

First, in the manuscript, we compared our ChIP-seq data to BDTNP ChIP-chip data. Second, the BDTNP data were collected from roughly staged embryos (2-3 hour staging), using two replicates per antibody (MacArthur et al., 2009). Our embryos are more carefully staged and limited to early NC14. Third, we used different criteria to select our peaks. After performing the ChIP-seq experiments, we selected the most reproducible peaks across 8 replicates to generate the peak list. We selected these peaks using the Irreproducible Discovery Rate (IDR) approach used by modENCODE to measure reproducibility between genomic datasets, as detailed in the Materials and methods. We are therefore using a different significance threshold to determine which peaks we include in our list, and this approach is different than the FDR ranking used for the BDTNP ChIP data (MacArthur et al., 2009). As such, we expect to generate a list of peaks that differs from theirs. However, as all of the peaks included in our list are highly reproducible across replicates, we are confident that our dataset allows accurate identification of real Bcd peaks at this stage of development. Overall, the Concentration-Sensitive I and II classes had higher ChIP signals than the Concentration-Sensitive III and Insensitive peaks, so these peaks were less likely to be detected in the BDTNP data. Although we acknowledge that some proportion of these types of peaks could be artifacts due to high accessibility, we have filtered our peaks by ATAC-seq accessibility score to mitigate this issue (described in the Materials and methods).

With respect to the proximity of these peaks to promoters, many early developmental genes have cis-regulatory elements in close proximity to their promoters, for example hunchback P2. It is therefore not clear whether proximity to a promoter rules out a peak as an enhancer, or predicts whether TF binding will be functional. We have added an additional table to the manuscript indicating the number peaks in each class overlapping with Vienna Tile-GAL4 reporters active at stage 4-6 and within 500 bp of a TSS. In both cases there are interesting differences between the sensitivity classes, and these differences are now discussed in the text.

Gene expression patterns for the Concentration Sensitive III members *hkb* and *cnc* have been previously published and shown to be sensitive to Bcd. In *bcd^E1^* mutants, expression of *cnc* is lost (Löhr et al., 2009), while anterior *hobo* expression is confined to a smaller expression domain. (Reuter and Leptin, 1994). We originally intended to include Hkb immunostaining in [Figure 1](#fig1){ref-type="fig"}, but had technical difficulties with our antibody.

> 9\) Text in the first paragraph of the subsection "Sequence composition of ChIP sensitivity classes does not account for in vivo sensitivity to Bcd concentration" is confusing. The authors say their results are not in agreement with those of Ochoa-Espinosa et al. (2005) study, but then in the next paragraph they say their results confirm theirs. Please rewrite for clarity.

The Ochoa-Espinosa study concluded that neither the *number* nor *strength* of Bcd binding sites in an enhancer correlated with the posterior boundary position of gene expression driven by that enhancer. Here we demonstrate that Concentration-Sensitive I and II targets are both enriched for enhancers driving anterior expression and more strongly enriched for Bcd binding sites. Our study therefore disputes the finding that the *number* of binding sites in enhancers does not correlate with gene expression pattern, but supports the finding that the *strength* of binding sites does not. This section has been re-written to clarify these two separate points.

> 10\) When demonstrating the relationship between Zld and Bcd at Bcd-bound regions, the authors claimed that \"Zld-dependent peaks are distributed across each sensitivity class determined by ChIP, with no particular class being significantly more Zld dependent,\" thus Zld \"is unlikely to determine the differential concentration sensitivity of Bcd peaks as a whole.\" This should be examined more closely. How many of the 855 Bcd peaks that overlap with ATAC open regions overlap with Zld binding? How many of the 402 Bcd peaks with reduced accessibility in zld- overlap with Zld binding? How many ATAC-seq peaks overlap with Zld binding? The authors are advised to show Zld binding, Zld motifs, and Bcd motifs in [Figure 3](#fig3){ref-type="fig"}, and/or provide additional analysis separating the four classes into those bound by Zld and not bound by/bound by low levels of Zld. Does the conclusion change, e.g., is any Bcd peak class significantly more Zld dependent? If so, this must be added.

Using a published list of Zld ChIP-seq peaks (Harrison et al., 2011), we find that 732 of our Bcd ChIP peaks (71.3%) overlap with Zld peaks. Interestingly, despite the higher representation of Zld motifs in the less sensitive classes, the peaks in the more sensitive classes (I and II) actually overlap with more Zld ChIP peaks:

Sensitive I = 125 (82.2%) Zld bound

Sensitive II = 113 (81.9%) Zld bound

Sensitive III = 396 (66.8%) Zld bound

Insensitive = 97 (67.8%) Zld bound

However, in terms of Zld dependence, the more relevant feature is whether a peak is open or closed in the absence of Zld. By this metric, none of the peak classes are significantly overrepresented in the Zld dependent group. A barplot showing enrichment of each class in the Zld dependent peaks has been added to [Figure 3](#fig3){ref-type="fig"}, alongside the plot of Bcd dependent peaks. We have also added a supplemental figure ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) showing overlap between Zld and Bcd ChIP peaks and comparisons of Bcd and Zld dependence (as defined by ATAC-seq) between Bcd peaks that are bound or not bound by Zld. These comparisons show that while there is a greater enrichment of Zld binding at the Concentration Sensitive I and II classes, only the Concentration Insensitive class shows a (slight) enrichment for Zld dependence when the classes are separated into those bound and not bound by Zld.

Of all ATAC-seq peaks that are open at NC14, 5182 (39.2%) overlap with Zld ChIP peaks.

However, only 2675 (20.2%) are dependent upon Zld for accessibility (closed in *zld^--^* embryos). We see the same pattern with the Bcd ChIP peaks: although 732 (71.3%) of Bcd ChIP peaks overlap with Zld ChIP peaks, only 402 (39.1%) are dependent on Zld for accessibility.

Of the 855 Bcd peaks that overlap with ATAC open peaks, 654 (76.5%) overlap with Zld binding. Of the 402 with reduced accessibility in *zld^--^* embryos, 371 (92.3%) overlap with Zld binding. Therefore, reduced accessibility in the absence of Zld appears to be a strong predictor of Zld binding, while Zld binding itself is not necessarily as predictive of Zld dependence, in agreement with (Schulz et al., 2015).

Zld and Bcd motif representation in each class was included in the original manuscript in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, which shows that Zld is the most highly represented motif in the Concentration-Insensitive and Concentration-Sensitive III classes, while Bcd is the top motif for the Concentration-Sensitive II and I classes.

> 11\) Structure function studies (protein deletion mutant here) are often difficult to assess because it is unclear whether the structure, and thus function, of the remaining protein (in this case the homeodomain), not just its presence, is unchanged, which is beyond the scope of this experiment. Therefore, the authors should qualify their conclusion by adding something like \"assuming the structure of the homeodomain remains completely intact...\"

We have now qualified this conclusion in the manuscript.

> 12\) The authors showed that a Concentration-Insensitive target caudal (cad), whose chromatin accessibility is Zld-dependent and Bcd-independent, can be converted to a Bcd concentration-sensitive target at anterior region by mutating Zld motifs into Bcd motifs. The authors reasoned that high Bcd levels in anterior regions conferred chromatin accessibility to the transgene. If Bcd-dependent chromatin accessibility at regions with high levels of Bcd is the key to its target expression, the authors should provide additional data to show that Bcd binds stronger to Cad (Zld-\>Bcd)-GAL4 than to Cad-GAL4 in both wt and zld- embryos; 2) that accessibility increases when adding Bcd sites (in the absence of Zld sites); and 3) though elaborate, adding Bcd sites to HC-45 instead of Zld sites should render the enhancer active if Bcd can pioneer chromatin.

We agree that being able to perform experiments 1 and 2 would be valuable. However, these experiments present significant technical issues, as described in detail below. Experiment 3 was performed, and confirms the hypothesis that addition of Bcd sites to HC45 renders the enhancer "active". We will discuss experiment 3 first, followed by our attempt at experiments 1 and 2.

To perform experiment 3, we generated three HC45 transgenic reporter lines (wild-type, +4 Zld sites, +4 Bcd sites). We used the HC45 wild-type and +4 Zld site sequences reported in Xu et al., 2014, and introduced 4 Bcd sites at the same positions used to make the +4 Zld site reporter to make the new +4 Bcd site reporter. We replicated the previously reported result, that HC45 is inactive in blastoderm embryos, and that adding 4 Zld sites confers activity to the reporter. Similar to addition of Zld sites, addition of Bcd sites also confers activity to the reporter (see [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}).

We performed this experiment at the suggestion of the reviewers, and are encouraged by the positive result, but we have some reservations about whether this provides stronger evidence of "pioneering" activity than our prior results with the cad enhancer. HC45, while inactive in blastoderm embryos, has open chromatin at this stage according to our ATAC data. The wildtype sequence has one Zld binding site, and seven Bcd binding sites. HC45 requires neither Zld (as cad does) nor Bcd for chromatin accessibility, in the sense that it retains chromatin accessibility in embryos maternally mutant for either factor. As such, it is unclear what drives the phenomenon of HC45 "acquiring activity" upon addition of Zld or Bcd sites. By analogy to the hsp70 system, where GAGA-factor pioneers the acquisition of open chromatin, thus allowing HSF to interact with binding sites and activate transcription, it would appear that neither Zld nor Bcd are operating like a pioneer (GAGA-factor), and are instead possibly functioning like transcriptional activators (HSF). On the other hand, we cannot rule out that addition of Zld or Bcd binding sites further enhances chromatin accessibility at HC45, or drives remodeling of chromatin to favor an 'active' versus an 'inactive' state. To address such questions, we would need to be able to measure differences in binding state and chromatin accessibility at these reporters (as suggested in experiments 1 and 2 above), and as described below, this is technically difficult. For these reasons, we have chosen to incorporate this new result with HC45 only as a supplement to [Figure 6](#fig6){ref-type="fig"}.

The major limitation to measuring chromatin accessibility or performing ChIP on reporter constructs (as suggested in experiments 1 and 2 for our cad reporters) is that the measurements must be able to distinguish between the transgenic (reporter) and endogenous (wild-type) copies of the regulatory element in question. This effectively limits our analysis to fragments of DNA that we can distinguish by SNPs. To pursue this, we sequenced the cad enhancer in genomic DNA preps from single adult flies, from every possible genetic background that would be present in the flies used in this experiment. The reporter constructs were generated by injecting plasmid DNA into flies with an attp2 landing site and then crossed to white females to isolate transformants. *zld* germline clones were produced by crossing *zld^294^*/FM7 females to C([@bib1])Dx/*ovo^D^* males. By sequencing genomic DNA from each of these genotypes and comparing it to our cad enhancer reporter sequences, we identified only one SNP that was present in the reporters and absent in all other genotypes. We were therefore constrained to using this SNP to design primers for qPCR. We tested these primers on genomic DNA, and the result is shown in [Author response image 3](#respfig3){ref-type="fig"}.
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Primer set 1 amplifies a product using the \"wild-type\" or non-transgenic SNP, primer set 2 amplifies a product using the transgenic SNP, and primer set 3 amplifies a product in the cad enhancer that is identical between the wild-type and transgenic sequences. These primers were successful at distinguishing between the wild-type and transgenic SNP sequences in genomic DNA, as primer 2 only gives a product in DNA from a fly with the cad-GAL4 construct. Similar results were obtained by qPCR on intact genomic DNA.

A second technical limitation is how to effectively measure differences in chromatin accessibility at a single locus by a qPCR based assay that can leverage the presence of the SNP to distinguish between the transgenic and endogenous enhancer copies. ATAC-seq sample preparations are themselves not suitable for PCR-based quantification approaches due to the insertion of adapter sequences at the time of chromatin fragmentation at accessible sites. On the other hand, the feasibility of Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE)-qPCR has to our knowledge not been reported in the literature, but it is likely that samples prepared by the FAIRE-seq technique would remain compatible with qPCR analysis. We therefore pursued this possibility in order to address this question. We fixed and sorted embryos by stage, homogenized, and sonicated genomic DNA as described for ChIP-seq in the Materials and methods. Following sonication, we isolated soluble chromatin by phenol-chloroform extraction as described in (Simon et al., 2013). We tested the effectiveness of this approach using wild-type (Oregon-R) embryos, and qPCR primers that would give predictable results based on chromatin accessibility measured by ATAC-seq in this study. We used three optimized primer sets that amplify short regions around the hunchback coding sequence. These regions amplified by these primers should be highly accessible (hb ChIP2), accessible (hb ChIP2), and inaccessible (hb P2 +4) at nuclear cycle 14. A plot showing the enrichment of the qPCR products over an input chromatin sample is shown in [Author response image 4](#respfig4){ref-type="fig"}, and gave the expected results.
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This result was encouraging. To perform the requested experiment to measure accessibility at cad (WT) and cad(*zld-*\>*bcd*), we performed FAIRE on wild-type (white) embryos and embryos expressing either the cad-GAL4 or cad(*zld-\>bcd*)-GAL4 in either a wild-type or *zld^--^* background. Unfortunately, when we performed the FAIRE experiment, the primers that effectively distinguish between the transgenic and endogenous cad enhancer in intact genomic DNA do not distinguish between the wild-type and transgenic alleles on a sheared DNA sample. Both the wild-type and transgenic primer sets gave a low signal compared to the highly accessible hb ChIP2 region, and are indistinguishable between embryos with and without the transgenic reporter:

![](elife-28275-resp-fig5){#respfig5}

Since we cannot even detect the transgene (or the endogenous copy) in a sheared DNA prep, and since we are limited to this single priming site to distinguish the alleles of this enhancer, we feel that we have exhausted our options for measuring the accessibility of the transgenic reporters directly, and are technically unable to address this point sufficiently.

Similarly, to measure differential binding of Bicoid to these reporters by ChIP (suggested experiment 1), we would be constrained by the same technical limitations as described for measuring chromatin accessibility via SNP based PCR. We emphasize that we recognize the potential power of such an experimental approach, but regrettably for this particular set of reporter constructs, despite our hardest efforts, we cannot address these questions within the limited time available for revision of this manuscript.

What is the most likely explanation for our results with the cad enhancer? Our data demonstrate that this enhancer is Zld-dependent, meaning that in *zld* mutant embryos, neither is the enhancer accessible, nor is the enhancer active. Suggested experiment 1 is designed to confirm an expected result, namely that adding Bcd sites results in greater Bcd binding in both wild-type and *zld* mutant embryos. This is likely to be the case. Suggested experiment 2 is designed to show the presumed positive correlation between chromatin accessibility and the activity state of the reporter construct. We are not aware of any documented example of an enhancer that shows activity without an accessible chromatin signature. Similar to the wild-type enhancer in *zld* mutant embryos, mutating the Zld motifs to a non-functional DNA sequence eliminates the activity of this enhancer in wild-type embryos (seeFigure 6---figure supplement 1A). When we instead convert the Zld motifs to Bcd motifs (Z-\>B), we recover enhancer activity, albeit in a different spatial pattern ([Figure 6](#fig6){ref-type="fig"}). The (Z-\>B) enhancer is active in *zld* mutants, and is now completely dependent on Bcd for activity ([Figure 6](#fig6){ref-type="fig"}). In sum, we feel that it is highly likely that the recovery of activity of the Cad(Z-\>B) enhancer stems from Bcd-dependent acquisition of chromatin accessibility, and that the shift in the spatial pattern reflects the demonstrated concentration-dependence of this function of Bcd. It seems significantly less likely that the Cad(Z-\>B) enhancer would somehow recover activity without recovering chromatin accessibility within at least the anterior \~1/3 of the embryo. We have now qualified this conclusion in the manuscript text to reflect the key assumptions we have made here. We hope that this is a suitable compromise, given the strength of our results with the transgenic Cad (and HC45) reporters and the technical limitations described above.

> 13\) Discussion of model in [Figure 7](#fig7){ref-type="fig"}. The idea that in regions where morphogen levels are low, Zld is required to boost activity has been proposed for both Dl and Bcd (Nien et al., 2011). Likewise, that morphogens at high levels can access and activate their high-level targets mostly on their own has also been discussed (same paper). This study corroborates and advances those ideas very nicely, and this should be mentioned.

This has been added to the Discussion.

> 14\) The authors should move the last sentence of the paper "This may be a common property of developmental transcription factors that must gain early access to their target enhancers while the chromatin state of the genome is being remodeled during large scale transitions in the gene regulatory landscape." to the Abstract.

We have made this change in the manuscript.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> The authors have satisfactorily addressed reviewer concerns. The efforts made to address further experiments (especially those suggested for the cad reporter) were greatly appreciated.
>
> Answers to author questions are answered below:
>
> 1\) Regarding the Kni stainings: We prefer to use the Kni stainings from the first experiment in [Figure 1](#fig1){ref-type="fig"}, because that experiment also utilized the same patterning markers (e. g., Btd) used in the other genotypes of the figure. We could move the Supplementary experiment to the main [Figure 1](#fig1){ref-type="fig"}, but would prefer to keep it in the Supplement. We have added sentences to the text and to the figure legend to point the reader to the more supplementary material.
>
> Reviewer\'s answer: Yes, please keep it in the supplement.

We have kept this figure in the supplement.

> 2\) Regarding the repressor binding: However, we agree that the data are not entirely clear, and difficult to interpret. Overall we agree that this analysis does not advance the concepts in the manuscript. We did not make it a main figure in the paper for this reason, and one possibility would be to remove the figure and corresponding argument entirely from the last paragraph of the subsection "Bcd binding to genomic targets is concentration dependent". We would appreciate advice from the reviewers on this point.
>
> Reviewer\'s answer: Please delete the corresponding argument from the last paragraph of the subsection "Bcd binding to genomic targets is concentration dependent", rather than keeping the new paragraph because it isn\'t much better with the single repressor focus.

We agree that the discussion of the BDTNP repressor binding is not a valuable addition to the manuscript. We have deleted the text, and panel A from [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} has also been deleted.

> 3\) Regarding the assays on cad and HC45 reporters: The major limitation to measuring chromatin accessibility or performing ChIP on reporter constructs (as suggested in experiments 1 and 2 for our cad reporters) is that the measurements must be able to distinguish between the transgenic (reporter) and endogenous (wild-type) copies of the regulatory element in question.
>
> Reviewer\'s answer: While it is possible to distinguish transgenic from endogenous enhancers by having one primer in the reporter sequence (GAL4), which is likely within ChIPed fragments, and one inside the enhancer (as in Xu et al., 2014 for Bcd ChIP on HC45), it is not necessary pursuing this venue at this point.
>
> With regard to the new HC45 data, the discussion about endogenous HC45 being accessible whether active or not and with or without Zld or Bcd is interesting, though it is formerly possible that local chromatin at the transgene is not behaving the same way as endogenous. Reviewers recommend having this data as a supplemental figure.

We agree with this point. We will keep the HC45 data in [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}.
